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I. INTRODUCTION 
BACKGROUND 
Prostate cancer has become a major health issue. Over the last decade the incidence of 
prostate cancer in Western world has been sharply increasing, and is nowadays the most 
common cancer in men from those countries, as well as the second leading cause of cancer-
related mortality (1). Since adequate prophylactic measures are not available, the role of early 
detection has been emphasized, as organ confined disease is still the best chance for the 
patient to benefit from curative treatment (2). 
The utilization of serum PSA level as screening tool, in addition to digital rectal 
examination and transrectal ultrasonography, results in an increased ability to detect prostate 
cancer while still organ-confined disease (3, 4). However, although elevated blood levels of 
PSA (greater than 4 ng/ml) correlate with the presence of prostate cancer, false positive 
results do occur and efforts have been made to accurately distinguish benign from malignant 
disease, even for slightly elevated PSA levels that can be indicative of either (4). Thus new 
approaches are needed that may allow a confident detection of malignancy, namely through 
DNA-based techniques (5). 
Indeed, it is acknowledged that a series of genetic alterations are associated with the 
transformation of normal glandular epithelium to prostate intraepithelial neoplasia, and from 
this in situ lesion to invasive carcinoma as depicted in the figure (6). Moreover, increasing 
efforts have been undertaken to characterize the molecular events implicated in the 
development of a malignant phenotype with propensity to metastasize and to become 
treatment-refractory (2). Due to the recognized heterogeneity of prostate cancer, the pathways 
that lead to malignant transformation are not uniform across the whole spectrum of the 
disease (7). Nevertheless, recent advances in the molecular characterization of prostate cancer 
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suggest that certain genetic alterations may be common in the evolution to malignancy. Thus, 
a potentially useful application of these studies would be the identification of molecular 
markers already present in early stage prostate cancer that could provide the means for more 
effective screening and diagnosis of the disease. 
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Genetic alterations 
Tumor suppressor gene (TSG) alterations have a major role in prostate cancer 
development, which fits perfectly well with the biology of a chronic, slowly growing 
neoplastic disease (8). According to Knudson's Two-hit hypothesis, TSG fuction is lost by 
independent inactivation events of both parental alleles (9). In sporadic tumors, bi-allelic 
inactivation is required to silence gene function in TSG and this is frequently accomplished 
by a somatic mutation in one allele and loss of heterozigozity (LOH) in the other (9). 
Several studies, using LOH analysis, indicated that the most common chromosomic 
losses (located at 8p, lOq, 7q, and 16q, and firstly described by cytogenetic studies) are 
regions of frequent allelic loss that normally harbor tumor suppressor genes (10). Indeed, 
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chromosome 8p abnormalities were found to be a preferential site of LOH in prostate cancer, 
occurring in the majority of adenocarcinoma cases examined (11). Additionally, Emmert-
Buck et al. identified frequent loss of portions at 8p21-pl2 in a high percentage of prostatic 
intraepithelial neoplasia (PIN) lesions, thus becoming an early event in prostate tumorigenesis 
(12). It has also been suggested that loss of 8p could be related to the development of 
androgen independence (13). Furthermore, deletions of portions of both lOp and lOq have 
been associated with advanced stage and rapidly progressive disease (14). Another tumor 
suppressor gene located on chromosome 10q23 (PTEN) was found to be the main inactivation 
target of lOq loss inactivated in three human prostate cancer cell lines derived from metastatic 
tissues (15, 16). Concerning 16q, the available data is not consistent. Carter et al. reported 
LOH in 30% of clinically localized tumor, and Bergerheim et al. found a higher rate (11, 17). 
Moreover, it is worthwhile noting that E-cadherin gene (a cell adhesion molecule critical for 
normal differentiation) was mapped at 16q22.1, which is a frequent site of LOH (18). 
Additionally, abnormalities in chromosome 7 have been observed in several studies. Trisomy 
7 was found to be common in both PIN and cancer lesions, and, on the contrary, aneusomy of 
chromosome 7 and loss of 7q31.1 were found to be associated with advanced stage and poor 
prognosis (19, 20). 
Other chromosomal losses have also been reported in prostate carcinoma: 3p, 5q, 9q, 
1 lp, 13q, 17p, and 18q. Interestingly, the p53 gene maps to 17p, the retinoblastoma gene (RB) 
to 13q, and DCC (deleted in colon cancer) to 18q (10, 21). These findings add further support 
to the importance of TSG alteration in the genesis of prostate cancer. 
Moreover, a number of these TSG were found to be mutated in prostate cancer, 
including P53, RB, pl6, and PTEN (10, 21). However, P53 mutations are uncommon in 
localized disease but become more frequent in metastatic deposits of prostate cancer (22). 
Concerning RB, loss of one copy of this gene is frequently found (-80%) in advanced prostate 
Carmen Jerónimo - Doctoral Thesis 
cancer, but point mutations are present in less than 20% of tumor samples (23). Furthermore, 
although pl6 is one of the most frequently altered genes in prostate cancer, it is rarely found 
to be mutated (24, 25). Finally, sequence analysis revealed that a second mutational event at 
the PTEN locus occurs in as much as 43% of the tumors with LOH of this gene (15). 
Additionally, it has been suggested that PTEN point mutations and homozygous deletion are 
late events, associated with advanced cancers (15, 16). Cairns et al. observed a higher 
frequency of these gene alterations in pelvic lymph node metastases than in clinically 
localized cancers, indicating that PTEN inactivation contributes to the acquisition of 
metastatic potential of prostate cancer (16). 
Epigenetic alterations 
Alongside with sequence loss, chromosomal deletions and point mutations, gene 
promoter hypermethylation is an alternative inactivation mechanism for TSG. Indeed, 
hypermethylation of CpG islands (areas of the genome rich in the sequence CpG, associated 
with the 5' regulatory regions of genes) has been found to correlate with gene transcriptional 
inactivation in several human cancers, including those of prostate (26, 27). Most of the initial 
studies focused on gene methylation patterns in prostate cancer cell lines. In this regard, 
Jarrard et al. showed that CpG methylation of pl6 occurred in three of five cell lines 
analyzed, although this alteration was found to be less common in prostate primary tumors 
(13%) (28). Concerning E-cadherin, a similar result was found: the promoter region was 
commonly methylated in prostate cancer cell lines, but low detectable rates of methylation 
were present in primary prostatic tumors (29). 
Interestingly, in prostate cancer, there are also genes inactivated by CpG methylation 
but not recognized as tumor suppressor genes at present time. Glutathione-S-transferase PI 
gene (GSTP1) is the prototype of this class of genes. GSTP1 codes for a phase II 
4 
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detoxification enzyme, which has an important role in preventing DNA damage due to cell 
exposure to a wide range of carcinogens (30). This gene was found to be hypermethylated in 
the vast majority of prostate carcinomas (-90%), and even in precursor lesions such as PIN 
(31, 32). However, GSTP1 promoter hypermethylation has also been reported in a non-
negligible number of benign prostate tissue samples (32). 
Another frequent (-70%) site of hypermethylation in prostate cancer is within the 
transcriptional region of the endothelin B receptor gene (ENDRB) (33), which mediates the 
clearance and secretion of the vasoconstrictor endothelin-1, another protein associated with 
prostate cancer progression. Hypermethylation is also an alternative mechanism for 
transcriptional repression of CD44, a metastasis suppressor gene, which seems to be involved 
in cancer progression (34). Finally, a recent report showed that inactivation of androgen 
receptor gene expression by hypermethylation was linked with advanced hormone 
independent prostate cancer (35). 
Clearly, the elevated frequency of hypermethylation of several of the above mentioned 
genes, together with its apparent specificity, led us to envision its use as molecular markers 
for the detection of prostate carcinoma cells. 
Mitochondrial mutations 
Besides the alterations in nuclear DNA found in cancer cells, recent studies have 
associated mitochondrial DNA (mtDNA) mutations with neoplasia. The mtDNA mutation 
rate is at least 10 times higher than nuclear DNA (36), which is most likely due to the 
production of reactive oxygen species (ROS) during oxidative phosphorylation, and to an 
inefficient mtDNA repair system (37, 38). 
Recently, several somatic mutations in mtDNA have been described in human cancer 
(39-42). These mutations were scattered throughout the mtDNA genome in the various 
5 
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studied tumors (40-42). The non-coding displacement-loop region (D-loop), an area 
considered to be a replication start site of the closed circular mitochondrial genome (36), was 
found to be a mutational hotspot (41). Regarding the coding mutations, most of them were 
confined to the respiratory complex I (39, 40). Additionally, because mtDNA has a higher 
copy number than nuclear DNA, and they were found to be homoplasmic in tumor cells, they 
are easier to detect, even in diluted clinical samples such as bodily fluids (41). 
Although the functional significance of these alterations is still largely unknown, these 
results could prove to be very useful in other neoplasms, particularly prostate cancer. To the 
best of our knowledge, an analysis of mtDNA mutations in prostate cancer cells, either in 
tumor tissue or in urine, has not been previously reported. 
AIMS 
Based on the previous section that summarizes very briefly (and for sure 
incompletely) the contemporary knowledge about prostate cancer molecular genetics and 
cytogenetics, one realizes that there is still a vast field of research. It would be unreasonable 
and unrealistic that this Doctoral Thesis would aim at the exhaustive characterization of 
prostate cancer at the molecular level. Moreover, we are limited by time and logistic means, 
and thus, a specific area of research was chosen. Since the biological and clinical material 
was provided by The Portuguese Institute of Oncology - Porto Regional Center, an institution 
mainly devoted to cancer diagnosis and treatment, we felt that basic and clinical research 
should allied, to provide the basis for future clinical trials, eventually including screening in a 
population setting. Thus, the main goal of this study was to identify genetic abnormalities and 
to define methodologies that may contribute for the early detection of prostate cancer. 
6 
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Specifically, the aims of this Doctoral Thesis were: 
1. To investigate the potential of GSTP1 methylation level quantitation as a prostate cancer 
specific marker, using real-time quantitative MSP. 
2. To assess whether detection of GSTP1 hypermethylation in voided urine may be used as a 
prostate cancer specific marker. 
3. To exam the clinical usefulness of GSTP1 hypermethylation quantitation as a prostate 
cancer specific marker in bodily fluids (voided urine and plasma), comparing 
conventional MSP with real-time quantitative MSP. 
4. To study the relation between GSTP1 polymorphism and epigenetic alterations linked to 
GSTTT expression in prostate cancer. 
5. To test the usefulness of the detection of ENDRB somatic methylation as a prostate cancer 
marker. 
6. To determine the frequency of mitochondrial mutations in prostatic adenocarcinoma, 
paired PIN lesions, voided urine specimens, and plasma samples and whether these 
changes can be used as tumor molecular markers. 
The results of this Doctoral Thesis are presented in 3 chapters, each of them dealing 
with a potential molecular marker of prostatic malignancy (GSTP1, ENDRB, and 
mitochondrial mutations). For each of the above mentioned aims a research project was 
7 
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designed and the resultant paper is presented in the accepted or submitted form for 
publication. 
Finally, in the last part of this Thesis, the more relevant conclusions of our studies and 
perspectives for future research projects are presented. 
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CHAPTER 1 
PAPER I: Quantitation of GSTP1 Hypermethylation Distinguishes Between Non-
Neoplastic Prostatic Tissue and Organ Confined Prostate Adenocarcinoma 
Journal of The National Cancer Institute, accepted for publication 
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ABSTRACT 
Background - Methylation of regulatory sequences near the pi-class glutathione S-transferase 
(GSTP1) gene is the single most common (>90%) reported epigenetic alteration found in 
prostate cancer. We compared quantitative GSTP1 methylation to standard histopathologic 
assessment of prostate tissues. 
Methods - Tissue samples from 69 patients with early stage prostatic adenocarcinoma, 28 
prostatic intraepithelial neoplasia lesions, and 31 patients with benign prostatic hyperplasia 
were tested for GSTP1 hypermethylation by quantitative fluorogenic real-time methylation 
specific PCR. To further verify the clinical applicability of this assay we performed a blinded 
investigation of prospectively collected prostate sextant biopsies of 21 patients with raised 
serum prostate-specific antigen (PSA) levels (11 with histologically identified 
adenocarcinoma, and 10 with no morphological evidence of adenocarcinoma). 
Results - The median ratios (methylated GSTP1/MYOD1) found in resected hyperplastic 
prostatic tissue, intraepithelial neoplasia, and adenocarcinoma were 0.0, 1.4, and 250.8, 
respectively (P < 0.00001). The median GSTP1 methylation ratios found in adenocarcinomas 
and normal prostate tissue in sextant biopsies from the 21 prospective patients with high PSA 
levels also differed significantly (410.6 and 0.0, respectively; P = 0.0007). 
Conclusion - Quantitation of GSTP1 hypermethylation may augment standard pathology by 
accurately discriminating between normal hyperplastic tissue and prostatic carcinoma within a 
small tissue sample. 
14 
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INTRODUCTION 
Prostate adenocarcinoma is the most commonly diagnosed cancer among men in 
Western countries, and the second leading cause of cancer related deaths in the United States . 
Treatment of the advanced stages of this disease has met with limited success. Hence, the 
development of reliable methods for early detection of the tumor while still organ-confined 
elevates the likelihood of cure after radical therapy2. Serum level measurement of prostate-
specific antigen (PSA) is the most powerful screening test available, but a large proportion of 
false positive elevations still limit this approach. Newer molecular tests may be able to more 
precisely identify the presence of neoplastic cells, namely in biopsies and/or bodily fluids. 
It is known that several genes are mutated in prostate adenocarcinoma. 
Notwithstanding, these alterations have been consistently found either just in a small number 
of cases, including ras oncogenic activation and TP53 inactivation3, or mainly in advanced 
disease, like PTEN inactivation4. Thus, the identification of more common genetic alterations 
in earlier stages of the disease, and in premalignant lesions like prostate intraepithelial 
neoplasia (PIN) is a major challenge, and may allow DNA-based detection of this major 
tumor type'. 
In this setting, loss of expression of the DNA detoxification enzyme glutathione S-
transferase (GST-rc) is associated with the methylation of the 5'-regulatory region of the 
GSTP1 gene and is the most common event described so far in prostate adenocarcinoma " . 
This alteration seems to be present even in precursor lesions such as PIN, but is rare in benign 
prostatic hyperplasia (BPH)9. Thus, this epigenetic alteration represents a new and potentially 
powerful molecular marker for the detection of prostatic tumor cells in an early stage of this 
disease. 
Promoter hypermethylation of several genes has already been successfully used to 
detect tumor DNA in bodily fluids from several types of cancer, namely bronchoalveolar 
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lavage, sputum, and serum from lung cancer patients , and serum from head and neck cancer 
patients". In these studies, a highly sensitive (1:1000) methylation specific PCR (MSP) 
method was introduced with high reproducibility12. However, this method does not permit a 
quantification of the extent of the gene methylation status. 
More recently, a specific real-time quantitative MSP method, allowing the 
performance of non-isotopic, rapid, and highly accurate quantitative amplification analysis via 
the continuous optical monitoring of a fluorogenic PCR assay was developed13. The 
application of this method to evaluate the methylation status of the pi6 gene in bone marrow 
aspirates from patients with multiple myeloma, revealed complete concordance with 
conventional MSP analysis14. In this same study, it was shown that real-time quantitative 
MSP was sensitive enough to detect up to 10 genome equivalents of a methylated pi6 
sequence. 
Here, we investigated the potential of quantitation of GSTP1 hypermethylation levels 
as a prostate cancer specific marker, using real-time quantitative MSP. We performed this 
study in prospectively collected tissue samples from patients harboring clinically localized 
prostate cancer, and a control group of patients with BPH. We then tested 21 patients with 
high (> 4.0 ng/ml) PSA values who underwent prostate sextant biopsies (11 with prostate 
cancer and 10 with histologically normal tissue). Our results suggest that quantitation of 
GSTP1 methylation-levels may accurately distinguish between benign and neoplastic prostate 
cells. 
16 
Carmen Jerónimo - Doctoral Thesis 
MATERIAL AND METHODS 
Patients and Sample Collection: 
Sixty-nine patients with clinically localized prostate adenocarcinoma (TRP) [Tic, 
according to the TNM staging system15], consecutively diagnosed and primarily treated with 
radical prostatectomy at the Portuguese Cancer Institute - Porto, were selected for this study. 
In addition, 31 patients with BPH that submitted to transurethral resection of the prostate 
(TURP), were included as controls. To further test the accuracy of GSTP1 methylation 
quantitation in small biopsy samples, prospectively collected sextant prostate biopsies from 21 
patients with raised serum PSA levels were analyzed in a blinded fashion. These cases 
consisted of 10 patients with no morphological evidence of adenocarcinoma (BWT) in the 
biopsy fragments, and 11 patients with histologically proven adenocarcinoma within the 
biopsy (CPB). 
Two pathologists (R.H., C.L.) reviewed all of the histological slides and each tumor 
was graded according to the Gleason grading system16. Fresh tissue, snap-frozen in isopentane 
and stored at -80°C, or paraffin-embedded prostatic tissue was collected from each surgical 
specimen. Sections were cut for the identification of areas of high grade PFN and 
adenocarcinoma (radical prostatectomy specimens), and BPH (TURP tissue). These areas 
were then carefully micro-dissected from 12-̂ .m thick sections for enrichment of PIN, 
adenocarcinoma and hyperplastic tissue. Only sections harboring 70% or more neoplastic 
cells were used for DNA extraction of PIN or cancer. An average of 50 sections for each area 
was used. Paraffin-embedded tissue was similarly micro-dissected, but was placed in xylene 
for 3 hours at 48 °C to remove the paraffin. The biopsies (BWT and CPB) were exhaustively 
cut (30-50 sections per biopsy) without microdissection and similarly prepared. DNA was 
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extracted using the method described by Ahrent et al. Briefly, DNA was digested overnight at 
48 °C in 1% SDS/Proteinase K (0.5 mg/ml), extracted with phenol-chloroform, and ethanol 
precipitated17. 
Bisulfite Treatment: 
Sodium bisulfite conversion of 2 |ig of genomic DNA was performed by a 
modification of a previously described method18. Briefly, NaOH was added to denature DNA 
(final concentration 0.2 M) and incubated for 20 minutes at 50 °C. A volume of 500 (il freshly 
made bisulfite solution (2.5 M sodium metabisulfite and 125 mM hydroquinone, pH = 5.0) 
was added to each sample and incubation was continued at 50° C for 3 hours in the dark. 
Modified DNA was purified using the Wizard DNA purification resin according to the 
manufacturer (Promega Corp., Madison, WI) and eluted in 45 ul of water at 80 °C. After 
treatment with NaOH (final concentration, 0.3 M) for 10 minutes at 37 °C, isolation was 
continued with 75 |il 7.5 M ammonium acetate followed by an incubation step of 5 minutes at 
room temperature. Finally, the modified DNA was precipitated by adding 2.5 volumes of 
100% ethanol and 2 |il glycogen (5 mg/ml). The pellet was washed with 70% ethanol, dried, 
and eluted in 30 |il 5 mM Tris (pH 8.0). 
Real-Time Quantitative MSP: 
Templates were amplified by fluorescence based real-time MSP (TaqMan ®-technology) as 
previously described19 using a 96-well reaction plate format in a PE Applied Biosystems 7700 
Sequence Detector (Perkin Elmer, Foster City, CA). In brief, primers and probes were 
designed to specifically amplify either bisulfite-converted DNA within the 3'-end of the 
promoter for the gene of interest, GSTP1, as well as for the internal reference gene, MYOD1. 
Primers and probes of the MYOD1 gene were located in an area without CpG nucleotides, 
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thus amplifying this gene independently of the methylation status of CpG nucleotides. The 
ratio between the values of GSTP1 versus MYOD1 obtained by the TaqMan® analysis were 
used as a measure for representing the relative level of methylated GSTP1 DNA, in the 
particular sample. These ratios were multiplied by 1000 for easier tabulation. The specificity 
of the reaction for methylated DNA was confirmed separately using LNCaP cell line DNA, 
which is methylated for the GSTP1 gene6. The primer and probe sequences were as follows: 








Fluorogenic PCRs were setup in a reaction volume of 25 [il using components supplied in a 
TagMan® PCR Core Reagent Kit (Perkin-Elmer, Foster City, CA). Fluorogenic probes were 
custom-synthesized by PE Applied Biosystems, primers by Life Technologies (Gaithersburg, 
MD). The final PCR reaction mixture consisted of 600 nM of each primer, 200 nM of probe 
200 |iM of each dATP, dCTP, dGTP, 400 nM dUTP, 5.5 mM MgCl2, 1 X TaqMan® Buffer A 
and 3 |il bisulfite-converted DNA. PCRs were performed using the following conditions: 50 
°C for 2 min, 95 °C for 10 min, followed by 50 cycles at 95 °C for 15 s and 60 °C for 1 min. 
Each PCR plate included a GSTP1 methylation positive (LNCaP) and a negative cell 
line (Du 145) for control purposes, as well as multiple water-blanks. With this assay we were 
able to detect methylated GSTP1 DNA down to 4 genome equivalents, determined by serial 
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dilutions of the positive control (bisulfite-converted LNCaP cell line DNA) considering a 
conversion factor of 6.6 pg of DNA per diploid cell . 
Statistical Analysis: 
The median and interquartile range of the methylation ratios was determined for each group of 
tissue samples (BPH, PIN, TRP, BWT, and CPB). These values were analyzed with the 
Kruskal-Wallis one-way analysis of variance, followed by the Bonferroni-adjusted Mann-
Whitney U test (non-adjusted statistical significance was considered for P values < 0.05). 
The same procedure was used to compare the age and PSA distributions among the patients 
with BPH, TRP, BWT, and CPB. Correlation analyses between the tumor methylation ratio 
and the PSA, on the one hand, and the Gleason score on the other hand, were performed, 
using Spearman's correlation analysis. Analyses were carried out using a computer-assisted 
program (Statistica for Windows, version 6.0). A cut-off level for GSTP1 methylation level at 
10.0, to distinguish benign from malignant tissue in prospectively tested biopsies, was chosen 
after analysis of the GSTP1 methylation levels in the initial resected samples (BPH, PIN and 
TRP). 
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RESULTS 
We initially studied GSTP1 promoter hypermethylation in prospectively collected 
samples from 69 patients with clinically localized prostate adenocarcinoma who underwent 
radical prostatectomy. As a control group, 31 patients with BPH documented by TURP and 
histologic analysis and were also included. 
Quantitative real-time MSP identified 63 of 69 (91.3%) adenocarcinomas (TRP) and 
15 of 28 (53.6%) paired high grade PIN lesions as positive for GSTP1 methylation. Moreover, 
9 of 31 (29%) patients with BPH also displayed GSTP1 methylation. The distribution of the 
ratios of methylated GSTP1/MYOD1 in BPH, PIN and TRP was however markedly different 
(Fig. 1). The medians and interquartile ranges (IQR) were, respectively, 0 (IQR: 0-0 .1) , 1.4 
(IQR: 0 - 45.9), and 210.8 (IQR: 53.5 - 697.5). The Kruskal-Wallis test revealed a 
statistically significant difference among the methylation ratios of these 3 groups of tissue 
samples (P = 0.00001). Using the Bonferroni-corrected Mann-Whitney U test, significant 
differences between BPH and PIN (P = 0.014), and between BPH and adenocarcinoma (P < 
1E-6) were found (Fig. 1). Likewise, a significant difference between PIN and TRP (P = 1E-
5) was observed. After reviewing the initial data, we set a cut-off level of 10.0 for 
GSTP1/MYOD1 ratios to distinguish benign (i.e., hyperplastic) from malignant tissue (TRP). 
Using this cut-off value, the sensitivity of the test was 85.5% and the positive predictive value 
was 100%. Specificity could not be determined since all prostatectomy specimens harbored 
adenocarcinoma. 
Based on our initial observations, we sought to investigate the potential of quantitative 
methylation to detect prostate cancer in small prostate biopsies. Twenty-one patients with 
raised serum PSA levels, submitted for a prostate sextant biopsy, were prospectively collected 
and tested in blinded fashion. Eleven patients harbored histologically proven prostatic 
adenocarcinoma (CPB, median PSA levels: 21.4 ng/ml), while 10 patients had no evidence of 
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malignant disease within their biopsies (BWT, median PSA levels: 10.8 ng/ml). Ten of 11 
(90.9%) CPB patients as well as 4 of 10 (40%) BWT patients harbored some level of GSTP1 
methylation. We were able to predict the histological diagnosis of prostate cancer in 10 out of 
11 sextant biopsies from patients with prostate cancer and excluded all 10 patients with BWT, 
(Fig. 2). The BWT methylation ratios were significantly different from those determined in 
adenocarcinomas, i.e., CPB (P = 0.0007, Fig. 2) as well as from TRP samples (P = 0.00001). 
Using the same cut-off value of 10.0, the sensitivity of the test when applied to this group of 
biopsies was 90.9%, the specificity was 100%, and the positive predictive value was 100%. 
Using the Bonferroni-corrected Mann-Whitney U-test there were no significant 
differences in serum PSA levels between BWT and CPB patients (P = 0.014). In contrast, 
significant differences in serum PSA levels were observed between BPH patients on the one 
hand, and CPB and TRP patients on the other hand (P = 0.00002, and P < 1E-6). In TRP 
patients, no correlation was found between the tumor methylation ratio and the Gleason score 
(r = 0.13, P = 0.36), nor between the tumor methylation ratio and the Gleason score (r = 0.13, 
p = 0.36). No correlation was observed between the tumor methylation ratios (TRP and CPB) 
and PSA levels (r = 0.04, P = 0.74; and r = 0.41, P = 0.20, respectively). The age distribution 
among all groups of patients also did not differ significantly (median age: 64 yrs, range: 52 -
82; P = 0.087). 
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DISCUSSION 
Our study demonstrated that GSTP1 promoter methylation is present in most prostate 
adenocarcinoma cases (91.3%, and 90.9% in TRP and CPB cases, respectively). Other studies 
using conventional non quantitative MSP also reported GSTP1 hypermethylation in over 90% 
of the cases6,7. Conventional MSP for GSTP1 is severely limited for specific cancer detection 
because many BPH lesions are also positive and cannot be distinguished from cancer cases. 
By using a robust quantitative assay, we demonstrated a clear difference in GSTP1 
methylation levels between benign (both BPH and BWT) and neoplastic prostate tissues. 
In agreement with previous studies, GSTP1 hypermethylation was found in a large 
proportion of PIN lesions9. In our cases, the paired adenocarcinomas also displayed the same 
alteration, but the methylation ratio was significantly lower in PIN lesions when compared 
with the tumor sample. These findings add further support to the precursor role of at least 
some PIN lesions in prostate adenocarcinoma. Furthermore, a loss or decreased expression of 
GSTTI protein in PIN lesions has been reported, although the basal cells present in these 
lesions retained the normal pattern of expression21. Thus, the lower levels of GSTP1 
hypermethylation detected in PIN lesions could also be related to the presence of non-
methylated alleles in basal cells. However, a significant number of these PIN lesions were 
negative for GSTP1 hypermethylation. This result could be associated with the well-known 
multi-focality of PIN lesions by other types of genetic analysis22. Future studies need to be 
done to see if the level of methylation in PIN lesions predicts progression to invasive cancer. 
Fourty-one patients without clinical or pathological evidence of prostate 
adenocarcinoma, showing either BPH or BWT were tested. Thirteen of these patients 
displayed methylation of the GSTP1 promoter in the normal (BWT: 4 cases) or hyperplastic 
(BPH: 9 cases) prostatic tissue. The former patients are good clinical controls because they 
represent the bulk of patients who present with high PSA values and a need to rule out 
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prostate cancer. Importantly, the median ratio of hypermethylated GSTP1 was significantly 
lower in non-neoplastic (i.e., BPH and BWT) tissue samples, when compared with PIN and 
adenocarcinoma (both CPB and TRP). Indeed, since GSTP1 hypermethylation appears to be 
an early genetic alteration9, it could also occur in morphologically normal tissue, as an early 
step in prostatic carcinogenesis. Although recent evidence suggests that CpG island 
methylation of the promoter region of certain genes in normal-appearing tissues may be 
associated with aging 23'24, we did not see age related methylation differences in this set of 
patients. 
The distinct segregation (Fig. 1 and 2) in GSTP1 methylation levels between non-
neoplastic lesions and prostate cancer suggests that this test could be quite useful in 
distinguishing men with a very low risk of prostate cancer, which cannot be discriminated by 
PSA measurement alone (Fig. 2). Indeed, the accuracy of the GSTP1 methylation test is 
excellent, with a positive predictive value of 100% (a cut-off value of 10.0). Moreover, since 
no correlation was found between PSA levels and GSTP1 methylation levels in prostate 
cancer patients, the latter potentially represents an independent marker for this disease. 
Indeed, BWT patients did not differ significantly from prostate cancer patients as far as serum 
PSA is concerned, but the methylation ratios confirmed that these biopsies were non-
neoplastic. 
The issue of false-negative prostate biopsies is also relevant in this regard. Indeed, a 
previous study demonstrated that 24% of men, in whom a prostate biopsy was performed due 
to abnormal serological (increased) PSA, ultrasonographic, or clinical findings, were found to 
harbor prostate cancer in repeated biopsies25. Moreover, since only a few neoplastic glands 
are usually harvested in a core prostate biopsy despite significant disease within the gland ', 
these foci could eventually be missed in a routine diagnostic basis due to the nature of 
histological sampling. Thus, the determination of GSTP1 methylation level could help detect 
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additional patients with cancer for further during clinical evaluation. Our blinded preliminary 
analysis of small biopsy samples from 21 individuals suggests important clinical utility, but 
further follow-up of these patients is required, including clinical, serological, pathological and 
molecular evaluation. 
The present study demonstrates that quantitation of GSTP1 hypermethylation is 
promising as an exceptionally useful marker for prostate cancer in clinically localized disease. 
The use of the real time PCR technology further enhances this approach as a powerful 
ancillary tool in molecular detection of prostate cancer. Intriguingly, methylated DNA was 
also recently detected in urine and plasma samples from patients with prostate cancer27, . 
Thus, this approach could be useful in patient monitoring and detection of minimal residual 
disease, once the GSTP1 methylation status of the primary tumor is established. Because so 
many patients at risk for prostate cancer present with a high serum PSA, quantitation of 
GSTP1 hypermethylation in tissue biopsies could augment cytologic techniques and triage 
patients into appropriate risk categories for further intervention . 
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BPH(n=31) PIN(n=28) TRP (n = 69) 
Fig. 1 Distribution of GSTP1 methylation levels in prostate tissues from benign prostatic 
hyperplasia (BPH), prostate intraepithelial neoplasia (PIN) and clinically localized prostate 
adenocarcinoma (TRP). Twenty-nine % of patients with BPH, 91.3% of patients with TRP 
and 53.6% paired PIN lesions were positive for GSTP1 methylation by real-time MSP. As 
indicated, the GSTP1/MYOD1 methylation ratios differed significantly. Solid bars indicate 
the median within a group of patients. Asterisks indicate the samples with 0-values which can 
not be plotted on a log scale (BPH: n = 22; PIN: n = 13; TRP: n = 6). 
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GSTP1/MYOD ratio - BWT/CPB: P = 0.0007 
3 
BWT CPB BWT CPB 
Fig. 2 Distribution of serum PSA and GSTP1 methylation levels in biopsy samples of patients 
without (BWT; n = 10) and with a histological diagnosis of prostate cancer (CPB; n = 11). 
The range of GSTP1/MYOD1 methylation ratios (O) between BWT and CPB was 
significantly different as well as serum PSA levels (A). Solid bars indicate the median within a 
group of patients. Asterisks indicate the samples with 0-values which can not be plotted on a 
log scale (BWT: n = 6 ; C P B : n = l ) . 
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ABSTRACT 
Novel approaches for the early detection and management of prostate cancer is 
urgently needed. Clonal genetic alterations have been used as targets for the detection of 
neoplastic cells in bodily fluids from many cancer types. A similar strategy for molecular 
diagnosis of prostate cancer requires a common and/or early genetic alteration as a specific 
target for neoplastic prostate cells. Hypermethylation of regulatory sequences at the 
glutathione S-transferase (GSTP1) gene locus is found in the majority (>90%) of primary 
prostate carcinomas, but not in normal prostatic tissue or other normal tissues. We 
hypothesized that urine from prostate cancer patients might contain shed neoplastic cells or 
debris amenable to DNA analysis. Matched specimens of primary tumor, peripheral blood 
lymphocytes (normal control) and simple voided urine were collected from 28 patients with 
prostate cancer of a clinical stage amenable to cure. Genomic DNA was isolated from the 
samples and the methylation status of GSTP1 examined in a blinded manner using 
methylation specific PCR (MSP). Decoding of the results revealed that 22 of 28 (79%) 
prostate tumors were positive for GSTP1 methylation. In 6 of 22 (27%) cases the 
corresponding urine sediment DNA was positive for GSTP1 methylation indicating the 
presence of neoplastic DNA in the urine. Furthermore, there was no case where urine 
sediment DNA harbored methylation when the corresponding tumor was negative. Although 
we only detected GSTP1 methylation in under a third of voided urine samples, we have 
demonstrated that molecular diagnosis of prostate neoplasia in urine is feasible. Larger studies 
focusing on carcinoma size, location in the prostate and urine collection techniques as well as 
more sensitive technology may lead to the useful application of GSTP1 hypermethylation in 
prostate cancer diagnosis and management. 
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INTRODUCTION 
Prostate cancer is the most commonly detected male cancer and the second leading 
cause of male cancer deaths in the US.1 Diagnosis and management are confound by the lack 
of symptoms and the lack of cancer specific diagnostic techniques during early stages of the 
disease. Prostate cancer is indeed curable if detected early while still localized within the 
capsule2. Novel approaches for the detection and control of this cancer is therefore extremely 
important. Adult sporadic cancers are known to arise through the accumulation of multiple 
genetic events,3 and these clonal genetic alterations can be used as targets for the detection of 
neoplastic cells in clinical samples.4 To develop such targets, a common and early genetic 
event unique to neoplastic cells must be identified and combined with a sensitive molecular 
assay able to detect this genetic event, among a high background of normal wild type cells. 
Several specific genetic alterations have been identified in prostate cancer5 including ras 
oncogenic activation, and inactivation of the tumor suppressor genes, Rb, p53, CDKN2a and 
PTEN. However, RAS or p53 mutations are infrequent5 and PTEN inactivation generally 
occurs relatively late in prostate cancer progression.6 Loss of heterozygosity (LOH) at critical 
suppressor loci, such as 8p and 16q, occurs frequently,5 but successful LOH detection requires 
a high proportion of tumor cells for robust analysis of a diagnostic sample. 
Hypermethylation of normally unmethylated CpG islands in the promoter regions of 
tumor suppressor genes correlates with loss of gene expression in human tumors. " 
Hypermethylation of regulatory sequences at the detoxifying glutathione S-transferase 
(GSTP1) gene locus is found in the majority (>90%) of primary prostate carcinomas but not in 
normal prostatic tissue or other normal tissues nor in benign hyperplasia of the prostate. 
GSTP1 methylation is thus the most common genetic alteration so far described in prostate 
cancer. The initial studies of GSTP1 methylation status in prostate tumors and cell lines were 
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performed using Southern blot analysis.10 A new method, methylation specific PCR (MSP), 
has since been described" which is more sensitive and requires less DNA. MSP utilizes a 
DNA modification step before PCR to determine the presence or absence of methylation of a 
gene locus at a sensitive level of up to 1 methylated allele in 1000 unmethylated alleles. 
Bodily fluids from several types of cancer have been successfully utilized for the 
molecular detection of neoplasia including stool in colon and pancreas, urine in bladder, and 
sputum and bronchial lavage fluid (BAL) in lung cancer.4 Recently promoter 
hypermethylation has been successfully used to detect neoplastic DNA in sputum, BAL 
and serum14 from lung cancer patients and serum from liver cancer,15 head and neck cancer 
and breast cancer patients.17 Most prostate tumors occur in the peripheral zone which contains 
3/4 of the glands, the minilobes of which form secretory ducts that empty their contents into 
the urethra. We hypothesized that urine from prostate cancer patients might therefore contain 
shed neoplastic cells or debris amenable to DNA analysis. We therefore examined the 
potential of GSTP1 hypermethylation as a cancer specific marker in simple voided urine 
specimens from 28 prostate cancer patients about to undergo radical prostatectomy for 
clinically curable disease. 
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MATERIALS AND METHODS 
Specimen Collection and DNA isolation 
Samples were obtained from patients undergoing radical prostatectomy. Urine was 
collected from each patient immediately before surgery. Tumor samples were obtained after 
pathological review, areas rich in neoplastic cells were selected and microdissected from 
formalin-fixed blocks. A peripheral blood sample in EDTA was also obtained for isolation of 
leukocyte DNA as a normal control. Genomic DNA was isolated as previously described.18 
Bisulfite Treatment 
One ug of each DNA sample was denatured by sodium hydroxide and modified by 
sodium bisulfite. DNA samples were then purified using Wizard DNA purification resin 
(Promega, Madison WI), again treated with sodium hydroxide, precipitated with ethanol, and 
re-suspended in water. 
Methylation Specific PCR 
MSP was performed separately with GSTP1 primers specific for the methylated 
reaction and the unmethylated reaction19 for each DNA sample. Unmethylated reaction : 5'-
GATGTTTGGGGTGTAGTGGTTGTT-3' (sense), 5'- CCACCCCAATACTAAATCA 
CAACA-3' (antisense); methylated reaction: 5'-TTCGGGGTGTAGCGCTCGTC-3' (sense), 
5'-GCCCCAATACTAAATCACGACG-3' (antisense). Thirty-five cycles of PCR were 
performed with an annealing temperature of 59°C. A water control without DNA for 
contamination and controls for unmethylated and methylated reactions were performed for 
each set of PCR. PCR reactions were analyzed on nondenaturing 6% polyacrylamide gels, 
stained with ethidium bromide and visualized under UV illumination. 
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RESULTS AND DISCUSSION 
We collected 28 primary resectable prostate tumors of pathological grade and stage 
amenable to surgical cure [7 T2A (Gleason 5-8), 5 T2B (Gleason 6-7), 15 T3A (Gleason 5-7) 
and 1 T3B (Gleason 7)] and extracted genomic DNA from tumor, peripheral blood 
lymphocytes (normal control) and urine sediment (from a simple voided urine obtained 
preoperatively). The DNA samples were coded and the methylation status of GSTP1 assessed 
in a blinded manner. Decoding of the results revealed that 22 of 28 (79%) prostate tumors 
were positive for GSTP1 methylation. In 6 of 22 (27%) cases the corresponding urine 
sediment DNA was positive for GSTP1 methylation indicating the presence of neoplastic 
DNA in the urine (Fig. 1, Tumors 1 and 2). There was no case where a urine sediment DNA 
gave a positive methylation result in the absence of methylation in the corresponding tumor 
(potential false positive) (Fig. 1, Tumor 3). The 6 tumors with positive urine results were 
Gleason 5-7 and stages T2A (1), T2B (1) and T3A (4). 
Although we only detected GSTP1 methylation in under a third of voided urine 
samples, we have clearly demonstrated that molecular diagnosis of prostate neoplasia in urine 
is feasible. Moreover, albeit in a limited study, we observed absolute specificity because we 
did not find any GSTP1 hypermethylation in the urine DNA from the 6 patients with 
unmethylated GSTP1 tumor DNA. We detected GSTP1 hypermethylation in a minority of 
paired urine and this level of sensitivity can likely be improved upon. Goessl et al20 reported a 
higher percentage of positive cases with a fluorescence based conventional PCR technique. It 
is possible that prostatic massage and the higher number of cycles used in their study yielded 
more positive urine DNAs but specificity is known to decrease in MSP, as in other PCR 
protocols, with increased cycle number.21 Indeed, in the study by Goessl, some urine samples 
were positive yet the primary tumor was not found to harbor GSTP1 hypermethylation. 
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Further work needs to focus on understanding factors such as tumor size and localization 
within the prostate, urine collection techniques for example the potential benefits of a 
prostatic massage before urine collection, and continuing improvements in molecular 
technology to increase the detection rate. 
Six tumors of 28 did not have GSTP1 hypermethylation preventing assessment of 
neoplasia in the urine. However, screening for methylation of other loci, such as the 
Endothelin B receptor (methylated in -70% of prostate tumors)22 or CD44 (methylated in 
77% of tumors)23 is likely to further increase the number of primary tumors with methylation 
(amenable for screening) to allow 100% diagnostic coverage. GSTP1 hypermethylation has 
not been reported in bladder cancer and is found infrequently in renal tumors.19 Inadvertent 
detection of a renal cell carcinoma in urine is therefore possible. Even so, GSTP1 
hypermethylation is cancer specific, unlike PSA it is not found in normal prostatic tissue or 
BPH. 
A further consideration is that of our choice of optimal negative controls. For a study 
of the type presented here, normal age-matched controls would present problems of ethics and 
interpretation of results. The high frequency of incidental prostate cancer in men over 50 
years of age (estimated at 30-50%), the hypothesized early timing of GSTP1 
hypermethylation in prostate tumorigenesis, and the ability of MSP to detect 1 cancer cell in a 
background of 1000 normal cells argues against initial inclusion of a cohort of age-matched 
men with no evidence of prostate cancer as controls. Whether a positive MSP test arose from 
a false positive or from asymptomatic prostate cancer would be difficult to ascertain. In our 
exploratory study, control urine samples from the 6 of 28 (21%) of patients whose prostate 
cancer did not show GSTP1 hypermethylation were negative for urine methylation. 
Thus, we envision the possibility of a sensitive non-invasive molecular test that may 
indicate the presence of prostate cancer in individuals with lesions undetectable by currently 
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existing methods and theoretically more specific for neoplasia than serum PSA. Only 80% of 
the patients in our study of clinically early cancer (Tla mostly) had elevated PSA. Two 
subgroups of men in whom GSTP1 hypermethylation has clinical utility would be the 20% of 
men with prostate cancer with a near normal PSA value and men with a high PSA value but 
negative biopsies. If our results are confirmed in larger studies, GSTP1 hypermethylation 
could be used to augment PSA and other current diagnostic procedures for detection of 
prostate cancer in the general population. 
This technique could also be employed to identify neoplastic disease in other diagnostic 
clinical material such as needle biopsies or serum. Similarly, in prostate cancer patients, 
hypermethylation may be a marker of neoplastic cell burden or minimal residual disease after 
removal of the primary tumor. Finally, it has previously been shown that nearly all bladder 
cancers24 and many kidney cancers25 can be detected by molecular analysis of urine raising 
the possibility of simultaneous molecular screening for three common adult cancer types in 
one simple voided urine specimen. 
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Patient 1 Patient 2 Patient 3 Patient 4 
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Fig. 1 Methylation specific PCR of GSTP1 in prostate carcinoma and urine DNAs. The 
presence of a visible PCR product in the methylated lane (M) of the tumor DNA from patients 
1, 2, and 4 indicates the presence of methylated alleles of GSTP1. A PCR product is also 
present in the methylated lane (M) of the urine DNA from patients 1 and 2 indicating the 
presence of neoplastic cell DNA in the urine. The absence of a visible PCR product in the 
methylated lane (M) of urine sediment DNA from patient 4 indicates that neoplastic cell DNA 
is absent or undetectable in the urine. Patient 3's tumor DNA is not methylated and the 
corresponding urine DNA also had no PCR product in the methylated lane (M) while a 
product can be clearly seen in the unmethylated lane (U). The PCR product in the 
unmethylated lane (U) from patient's 1, 2 and 4 tumor DNA most likely arises from normal 
cell contamination of the tumor specimen. Tumor cell line MCF-7 DNA as a positive control 
for GSTP1 methylation, normal lymphocyte DNA (NL) as a negative control, a water control 
for contamination in the PCR reaction (right) and Mspl digested pBR322 as a molecular 
weight marker (far left) are also shown. 
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ABSTRACT 
Purpose: Recent studies have shown a high frequency (>90%) of GSTP1 gene promotor 
methylation in prostate adenocarcinoma, and a lower frequency in DNA from serum and 
urine. We sought to further determine the value of real-time quantitative methylation specific 
PCR (MSP) of GSTP1 as a molecular tool for the detection of prostate adenocarcinoma. 
Experimental design: Tissue samples from 69 patients with early stage prostatic 
adenocarcinoma and 31 patients with benign prostatic hyperplasia (BPH) were collected. 
Matched urine and plasma specimens were obtained preoperatively. After sodium-bisulfite 
treatment, extracted DNA was analyzed for GSTP1 promoter hypermethylation both by 
conventional and real-time quantitative MSP. 
Results: In tissue samples, GSTP1 hypermethylation was detected in 63/69 (91.3%) of the 
cancer patients, and 9/31 of BPH patients (29%). Conventional MSP detected GSTP1 
hyermethylation in a larger number of urine and plasma than real-time quantitative MSP 
(53.6% vs. 31.9%, overall). In all positive bodily fluids, the paired tumor was also confirmed 
to be methylated. GSTP1 hypermethylation was detected by both MSP methods in only 1 
(3.2%) urine sample from a BPH patient. 
Conclusions: Although not quantitative, conventional MSP is currently more sensitive than 
real-time quantitative MSP in the detection of GSTP1 hypermethylation in bodily fluids from 
prostate cancer patients with clinically localized disease. The value of quantitative 
determinations in monitoring and risk assessment remains to be further explored. 
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INTRODUCTION 
Prostate adenocarcinoma is the most commonly diagnosed cancer among men in the 
Western countries, and the second leading cause of cancer related deaths in the United States. 
Treatment of the advanced stages of this disease has met with limited success. Hence, the 
development of reliable, noninvasive methods for early detection of this cancer while still 
organ-confined is likely to increase the cure rate after definitive therapy. 
Although several specific genetic alterations have been described in prostate 
adenocarcinoma, such as TP53 and PTEN inactivation, the single most common and earlier of 
these is methylation of the 5'-regulatory region of the GSTP1 gene.3"8 The detection of this 
epigenetic alteration in bodily fluids has been successfully accomplished using DNA-based 
techniques.9"12 However, these earlier studies either included only a relatively small number of 
patients or focused mainly on cases of advanced disease.9"10 Thus, the potential usefulness of 
this marker in the detection of the earlier stages of prostate cancer remains to be explored. 
Recently, a specific real-time quantitative methyl specific PCR (MSP) method, 
allowing the performance of non-isotopic, rapid, and highly accurate quantitative 
amplification analysis via the continuous optical monitoring of a fluorogenic PCR assay was 
developed.13 The application of this method to evaluate the methylation status of the pl6 gene 
in bone marrow aspirates from patients with multiple myeloma, revealed complete 
concordance with conventional MSP analysis.14 In this same study, it was shown that real-time 
quantitative MSP was sensitive enough to detect down to 10 genome equivalents of 
methylated pl6 sequence.14 
Hence, we investigated the potential of GSTP1 hypermethylation detection in voided 
urine and plasma DNA as a prostate cancer specific marker in two groups of patients, one of 
them harboring clinically localized prostate cancer, and a control group consisting of patients 
with benign prostatic hyperplasia (BPH). Real-time quantitative MSP was used to quantify the 
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GSTP1 methylation level. The results were compared to conventional MSP. The rationale for 
the former approach is that real-time quantitative MSP allows for rapid analysis of a larger 
number of samples in a highly reproducible assay using small amounts of template DNA. 
Moreover, quantification may allow discrimination between benign and neoplastic disease, 
and could be useful in monitoring this disease. 
MATERIAL AND METHODS 
Patients and Sample Collection: 
Sixty-nine patients with clinically localized prostate adenocarcinoma, consecutively 
diagnosed and primarily treated with radical prostatectomy at the Portuguese Cancer Institute 
- Porto, were selected for this study. All cases were identified by raised serum PSA in routine 
analysis and confirmed by sextant prostate biopsy (stage Tic). Additionally, 31 patients with 
BPH, submitted to transurethral resection of the prostate (TURP), were included for control 
purposes. DNA was extracted from either hyperplastic or tumor tissue, plasma and voided 
urine collected from each patient, as previously described.16 Briefly, DNA was digested 
overnight at 48°C in 1% SDS/Proteinase K (0.5mg/ml), extracted by phenol-chloroform, and 
ethanol precipitated. 
Bisulfite Treatment: 
To perform the sodium bisulfite conversion of genomic DNA, a modification of a 
previously described method was used.17 In brief, DNA was denatured by incubation with 
NaOH for 20 minutes at 50°C (final concentration 0.2M). A volume of 500 \ú freshly made 
bisulfite solution (2.5M sodium metabisulfite and 125mM hydroquinone, pH=5.0) was added 
to each sample and incubation was continued for 3 hours, at 50°C, in the dark. Modified DNA 
was then purified using the Wizard DNA purification resin, according to the manufacturer's 
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instructions (Promega Corp., Madison, WI), and eluted in 45 ,̂1 of water at 80°C. After treating 
with NAOH (final concentration, 0.3M) for 10 minutes at 37°C, isolation was continued with 
75|il 7.5M ammonium acetate followed by an incubation step of 5 minutes at room 
temperature. Finally, the modified DNA was precipitated by adding 2.5 volumes of 100% 
ethanol and 2(il glycogen (5mg/ml). Each pellet was washed with 70% ethanol, dried, and 
eluted in 20ul 5mM Tris (pH 8.0). 
Real-Time Quantitative MSP: 
Templates were amplified by fluorescence based real-time MSP (Taqman®), as previously 
described.18 Briefly, primers and probes were designed to specifically amplify either bisulfate-
converted promoter DNA for the gene of interest, GSTP1. For tissue samples, the relative 
level of methylated GSTP1 DNA was expressed as the ratio between the values of GSTP1 
versus MYOD1 obtained by the TaqMan® analysis, in each particular sample, and then 
multiplied by 1000. All plasma and urine samples were also subjected to real-time PCR 
analysis, both for GSTP1 methylation and MYOD1 gene, used as control for the amplifiability 
of the DNA. The GSTP1 methylation level in bodily fluids was expressed as copies of 
methylated GSTP1 (genome equivalents - GE) per 50 ml for urine samples, and per 1 ml for 
plasma samples.19 The specificity of the reaction for the methylated DNA was confirmed 
separately using a positive control (the LNCaP cell line, known to be methylated for the 
GSTP1 gene) and a negative control (the Du 145 cell line). Multiple water blanks were 
included on each plate. The primer and probe sequences were as follows: 
(a) GSTP1 methylation specific: 5'-AGTTGCGCGGCGATTTC-'3 (sense); 
5 ' -CGGTCGACGTTCGGGGTGTAGCG- ' 3 (Taqman®probe) ; 
5'-GCCCCAATACTAAATCACGACG-'3(antisense). 
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(b) MY0D1: 5'-CCAACTCCAAATCCCCTCTCTAT-'3 (sense); 
6FAM5 '-TCCCTTCCTATTCCTAAATCCAACCTAAATACCTCC-3 TAMRA 
(Taqman® probe); 
5'-TGATTAATTTAGATTGGGTTTAGAGAAGGA-'3 (antisense). 
The lowest number of genome equivalents detected by real-time quantitative MSP was 3.16 
GE, determined by serial dilutions of the positive control (LNCaP cell line DNA). This figure 
was calculated based a conversion factor of 6.6 pg of DNA per cell. 
Conventional MSP: 
Primer sequences for either methylated or modified unmethylated GSTP1 have been 
described previously.7 Conventional MSP was carried out using the appropriate negative and 
positive controls as described above. Forty cycles of PCR were performed using an annealing 
temperature of 62°C. The PCR products were directly loaded onto a non-denaturing 6% 
polyacrylamide gel, stained with ethidium bromide, and visualized under UV illumination. 
Statistical Analysis: 
A simple Mann-Whitney U test was carried out to compare the age distribution and 
serum PSA levels between the patients with BPH and those with adenocarcinoma. Statistical p 
values of P < 0.05 were considered to be significant. Analysis was carried out using a 
computer-assisted program (Statistica for Windows, version 6.0). 
RESULTS 
We prospectively studied 69 patients with clinically localized prostate adenocarcinoma 
with a median age of 63 years (range: 52-74). As a control group, 31 patients with BPH were 
included (median age = 64 years, range: 53-82). No statistically significant difference was 
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found between the age distribution of these two groups of patients (p = 0.33). The median 
value of the preoperative serum prostate-specific antigen (PSA) was 10.3 ng/mL (range: 1.69-
48.3), and 3.43 ng/mL (range: 0.67-31), for cancer and BPH patients, respectively (p < 1E-5). 
We determined the promotor methylation status of the GSTP1 gene in the tissue samples, both 
for prostate cancer patients and for controls, by conventional MSP and real-time quantitative 
MSP (Figures 1 and 2, respectively). Sixty-three of 69 (91.3%) adenocarcinomas were found 
to be positive for GSTP1 methylation. In the control group, 9 of 31 (29%) patients with BPH 
were also found to be positive in tissue for methylation of the GSTP1 promoter region. No 
discordance was found between the two MSP methods. 
After screening for methylation changes in the tissue, we analyzed the paired urine and 
plasma DNA samples, using both real-time quantitative MSP and conventional MSP in 
blinded fashion. In every case we were able to amplify DNA from all samples, i.e., tissue, 
urine, and plasma. GSTP1 hypermethylation was found in 13 of 69 (18.8%) urine sediments, 
and 9 of 69 (13.0%) plasma DNA samples from prostate cancer patients, using real-time 
quantitative MSP (Figure 3). The median and interquartile ranges (IQR) of GE of methylated 
GSTP1 were 3.039 GE/ml (IQR: 0.857 - 3.529), and 140.533 GE/ml (IQR: 54.6 - 552,267), 
for urine and plasma samples, respectively. Conventional MSP was able to detect GSTP1 
methylation in 21/69 (30.4%) urines, and in 25/69 (36.2%) plasmas from the same samples. 
Moreover, all cases positive for GSTP1 hypermethylation by real-time quantitative MSP 
(plasma and/or urine) where also positive by conventional MSP analysis. Importantly, there 
was no case in which the urine sediment or plasma DNA harbored methylation when the 
corresponding tumor was negative. 
In patients with BPH, GSTP1 hypermethylation was detected in 1/31 (3.2%) urine 
sample, and both MSP methods were concordant (5.549 GE/ml). The matched BPH tissue 
sample did not harbor GSTP1 hypermethylation (representing a potential false positive or 
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laboratory labeling error: see discussion below). All the plasma samples from BPH patients 
were negative (using both methods) for GSTP1 hypermethylation. 
DISCUSSION 
As expected, we found GSTP1 promoter methylation in more than 90% of the tumor 
tissue samples and to a lower degree in paired serum and urine as previously reported. " 
These findings confirm the high frequency of this genetic alteration, and continue to support 
its application in DNA-based prostate cancer detection approaches. The median levels of 
GSTP hypermethylation in serum were significantly higher than urine DNA levels, by 
quantitative analysis (Fig. 2). Our study clearly shows that higher amounts of DNA are present 
in plasma than in urine, specially when considering the much larger total volume that is 
sampled. This finding could be related to the extraction of DNA from urine sediments, i.e., 
predominantly from tumor cells shed in urine. Thus, it is suggested that free tumor DNA is 
preferentially released into the circulation rather than the prostate ductal system. These results 
are also consistent with the propensity of prostate cancer to disseminate early throughout the 
body. 
Among the prostate cancer patients who had GSTP1 hypermethylation in the primary 
tumor DNA, 37 (53.6%) also displayed this alteration in urine or plasma DNA using 
conventional MSP. The number of positive cases in plasma slightly outnumbered those found 
in urine samples (36.2% vs. 30.4%). The same trend was reported in a previous study, in 
which 72% of patients were found to be positive in plasma or serum, and only 36% in urine. 
However, there are some major differences between Goessl et al. and our study, preventing 
direct comparisons between them. Goessl et al. included a large number (45%) of stage IV 
patients (not amenable to curable surgical resection) in which the likelihood of circulating 
tumor cells is rather high, perhaps resulting in a higher detection rate. Indeed, all advanced 
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stage patients were positive for GSTP1 methylation in serum in their study. The rate of 
detection in urine samples was also superior to that of our study, but in their cases prostatic 
massage was performed previous to sample collection, increasing the shedding of prostate 
cells in to the urine.12'21 
The rate of detection in urine found in this study, reinforces the results of our previous 
preliminary work." Thus, several strategies can be considered to improve the detection rate of 
GSTP1 hypermethylation in bodily fluids." One approach would be to increased the number 
and/or volume of urine and plasma samples, enabling a larger sampling of tumor DNA. 
Moreover, prostatic massage might increase cell shedding in urine as suggested, but this 
procedure could limit the acceptability of the test. Although a higher rate of GSTP1 
hypermethylation was detected in ejaculates (approaching 50%), the nature of the sampling 
procedure, especially in older men, may preclude its widespread use.12' 22 Eventually, further 
technical refinements of the PCR method could contribute to an increase in sensitivity, 
although these procedures have been substantially optimized. 
The specificity of GSTP1 hypermethylation remains high since it was rarely detected 
in the urine and plasma DNA from patients in whom this marker was not altered in the tumor 
tissue. Moreover, GSTP1 methylation has not been generally detected in other genitourinary 
malignancies, including bladder carcinomas.7 
Thirty-one patients with BPH, with no evidence of harboring prostate adenocarcinoma 
were used as controls. Although GSTP1 promoter hypermethylation was reported to be rare in 
normal tissue8, 12 , 9 of these patients (29%) displayed this alteration in their prostatic tissue 
Our findings could be explained by age-related GSTP1 hypermethylation, since recent 
evidence suggests that CpG island methylation of the promoter region of certain genes in 
normal-appearing tissues is associated with aging.23, 24 However, we saw no age-related 
patterns in our sample set (both BPH and cancer). Moreover, we can not disregard the 
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possibility that small foci of adenocarcinoma with GSTP1 hypermethylation could have been 
resected during the TURP procedure, along with hyperplastic glands. 
In one patient with BPH, GSTP1 hypermethylation was detected in the urine sample 
but not in matched tissue, and both MSP methods were concordant. This result could be 
interpreted as a false positive, diminishing the specificity of this method. In our patients with 
prostate cancer no hypermethylation was detected in urine or plasma DNA of paired 
unmethylated tumors. Thus, it is tempting to suggest that this BPH patient could harbor occult 
prostate adenocarcinoma, localized in the peripheral region of the organ, which is not sampled 
by TURP. Further careful follow-up of this patient may clarify this interesting observation. 
In previous studies, promoter hypermethylation of several genes has been successfully 
used to detect tumor DNA in bodily fluids from several types of cancer, namely bronchial 
lavage fluid (BAL), sputum, and serum from lung cancer patients, and serum from head and 
neck cancer patients 10. In these studies, conventional MSP method was found to have a high 
sensitivity (1:1000).9'25 However, this method does not permit a quantification of the extent of 
gene methylation status. In our present study, a larger number of urine and plasma samples 
were found to be positive for GSTP1 hypermethylation using conventional MSP, when 
compared with real-time quantitative MSP (53.6% vs. 31.9%). This finding suggests that the 
former method is significantly more sensitive than the latter, perhaps due to the greater 
specificity of the internal probe designed for quantitative analysis and the high background 
level of fluorescence intrinsic to the Taqman analysis. 
Notwithstanding, the lower limit of real-time quantitative MSP detection determined in 
the present study (3.16 GE) was more sensitive than the level reported by Lo et al. (10 GE) in 
myeloma.14 However, the amount of DNA from prostate cancer cells present in urine and 
plasma may be very low, impairing its detection by real-time quantitative MSP. Indeed, Lo 
and co-workers were able to detect hypermethylation in reasonable amounts of cells obtained 
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from bone marrow aspirates of patients with multiple myeloma.14 These results suggest that 
real-time quantitative MSP could be particularly useful in the identification of neoplastic 
disease in cell-rich clinical material, such as needle biopsies. In this regard, real-time MSP has 
the advantage of enabling the quantification of the number of GSTP1 methylated copies, 
which may allow the discrimination between methylated normal tissue and carcinoma. 
We have demonstrated that GSTP1 hypermethylation may be detected in urine and 
plasma samples in a large proportion of early stage prostate cancer patients harboring DNA 
methylation in the tissue. Because so many patients die of prostate cancer each year, these 
results could have significant implications for the development of molecular approaches as 
adjuncts to cancer detection. Furthermore, such assays may be useful in patient monitoring 
and detection of minimal residual disease, once the GSTP1 methylation status of the primary 
tumor is established. Clearly, larger more definitive studies are now needed to further 
determine a role for GSTP1 methylation in the clinical setting. 
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#54 #40 
Ur P ' T Ur P M+ U+ H2Q 
Fig. 1 Illustrative example of MSP for GSTP1 promoter region: tumor (T), urine (Ur), and 
plasma (P) of patients #54 and #40. Lanes U and M correspond to unmethylated (97 bp) and 
methylated (93 bp) reactions, respectively. In each case, Du 145 cell line DNA was used as 
negative control for methylation (U+), DNA from LNCaP cell line was used as positive control 
for methylation (M+), and water was used as negative PCR control (H20). On the right side 
the HiLo marker is depicted. 
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BPH (n =31) TRP (n =69) 
Fig. 2 Distribution of GSTP1 methylation levels in prostate tissues from benign prostatic 
hyperplasia (BPH) and clinically localized prostate adenocarcinoma (TRP). GSTP1 
methylation was detected by real-time MSP in 29% of patients with BPH and 91.3% of 
patients with TRP. Solid bars indicate the median within a group of patients. Asterisks 
indicate the samples with 0-values which can not be plotted on a log scale (BPH: n = 22; TRP: 
n = 6). 
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Urine (n=13) Plasma^=9) 
Fig. 3 Distribution of GSTP1 methylation levels (real-time MSP) in paired urine and plasma 
samples. Solid bars indicate the median within a group of patients. Asterisks indicate the 
samples with 0-values which can not be plotted on a log scale (urine: n = 56; plasma: n = 60). 
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ABSTRACT 
GSTP1 gene codes for an enzyme (GSTTC) involved in detoxification of carcinogens, 
displays a polymorphism that results in an amino acid substitution, I105V. The variant enzyme 
has lower activity and less effective capability of detoxification. Thus an association between 
GSTP*B allele and several neoplasms was reported, but in prostate cancer patients the data are 
conflicting. Moreover, since GSTP1 promoter hypermethylation is a frequent alteration in 
prostate carcinoma, inactivating GSTrc expression, we hypothesized that this epigenetic 
modification could overcome the reduced enzyme activity caused by the polymorphism. To 
assess the risk of prostate cancer development, 3 populations comprising prostate cancer 
patients (PA), benign prostatic hyperplasia (BPH) patients (PB) and healthy blood donors 
(PC) were enrolled and the respective GSTP1 genotype was determined. Tissue samples from 
the 105 PA patients (105 adenocarcinoma and 34 prostatic intraepithelial neoplasia lesions), 
and from 43 PB patients were tested for GSTP1 hypermethylation by methylation specific 
PCR. GSTTI expression was assessed by immunohistochemistry. No significant effect on 
prostate cancer risk was detectable for GSTP1 genotype, both comparing to the blood donors 
population (PC) (OR=1.13, 95% CI=0.62-2.06), and using the PB group as control population 
(OR=0.79, 95% CI=0.35-1.75). Moreover, no association was found between this genotype 
and tumor or BPH methylation status. In adenocarcinoma, a strong association between 
GSTP1 promotor hypermethylation and loss of GSTTI expression was observed. This trend 
was not retained in PIN or BPH lesions. 
We concluded that promoter hypermethylation is an effective cause of GSTP1 
transcription silencing. Moreover, GSTP1 polymorphism is not associated with promoter 
hypermethylation nor with altered susceptibility to prostate cancer. It is suggested that 
epigenetic mechanisms may overcome the potential effects of GSTP1 variants in GSTTI 
activity. 
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INTRODUCTION 
Prostate adenocarcinoma is the most frequently diagnosed cancer among men in Western 
world, and the second leading cause of cancer death in the United States, thus becoming a 
major health issue in these countries (1). Etiologically, prostate cancer is a multifactorial 
disease in which several environmental and genetic factors are involved, although little is 
known about the interaction between these factors (2). Moreover, the role of epigenetic 
phenomena, namely DNA de novo methylation, in the modulation of gene expression is a 
major research field in prostate carcinogenesis (3). 
GSTP1 gene, located at 1 lql3, belongs to a supergene family of enzymes, the glutathione 
S-transferases (GST), involved in detoxification of electrophilic compounds, such as 
carcinogens and cytotoxic drugs, by glutathione conjugation (4, 5). In addition, they are 
believed to play a role in the protection of DNA from oxidative damage (6). GSTP1 gene has a 
polymorphic site at codon 105 (exon 5), where an A-G transition causes an isoleucine to 
valine substitution (I105V), giving rise to the GSTP1*B allele (4-6). Moreover, recent studies 
found that individuals with the valine allele display a significantly lower enzyme activity and 
less effective capability of detoxification (7). Hence, an association between GSTP*5 allele 
and lung, bladder, and testicular neoplasms has been reported (6, 8). However, in prostate 
cancer patients, a significant decrease in frequency of the GSTP1*A has been reported instead 
(8), although this result has been challenged by other authors (9-12). 
Over the last few years, several studies revealed that GSTP1 (usually expressed in normal 
human epithelial tissues, including prostate) could be somatically inactivated by 
hypermethylation of the promoter region (13-15). This alteration, which is often associated 
with the loss of GSTTI expression, is the most common event (-90%) described so far in 
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prostate carcinoma (15, 16). Furthermore, GSTP1 inactivation may lead to increased cell 
vulnerability to oxidative DNA damage and to the accumulation of DNA base adducts, and, as 
result, more prone to acquire other relevant genetic alterations in prostatic carcinogenesis (17). 
Thus, we hypothesized that this epigenetic modification could superimpose on the differential 
enzyme activity due to the allelic variants of the I105V polymorphism and eventually explain 
the conflicting reports on GSTP1 polymorphism effect in prostate cancer. 
Hence, we firstly investigated the association between I105V GSTP1 polymorphism and 
the risk for developing prostate cancer, to rule out a primary effect of genotype in prostate 
cancer susceptibility. Then, a possible association between this polymorphism and de novo 
methylation was assessed. Finally, immunohistochemical analysis was done to determine 
whether GSTP1 hypermethylation affects gene expression. This study was performed in a 
relatively large series of early stage (clinically localized) prostate cancer patients, and follows 
previous studies of ours that investigated the role of GSTP1 hypermethylation as a prostate 
cancer marker (18, 19). 
MATERIAL AND METHODS 
GSTP1 Polymorphism 
Blood samples and DNA extraction: 
For this study, 3 populations of male subjects were enrolled at The Portuguese Cancer 
Institute - Porto. One population (PA) consisted of 105 patients with histologically confirmed 
adenocarcinoma. Two more groups, one (PB) comprising 43 patients with benign prostate 
hyperplasia (BPH), and a control population (PC) consisting of 98 male healthy volunteer 
blood donors from the same institution, were also included. Blood was collected from all 
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individuals and genomic DNA was extracted from fresh peripheral leukocytes as previously 
described (20). Briefly, DNA was digested overnight at 48°C in 1% SDS/Proteinase K 
(0.5mg/ml), extracted by phenol-chloroform, and ethanol precipitated. 
GSTP1 genotype analysis: 
The exon 5 polymorphic site in GSTP1 locus (He-105->Val) was detected by restriction 
fragment length polymorphism (RFLP) of polymerase chain reaction (PCR) amplified 
fragments. 
The primers used were: P105 F 5'- ACC CCA GGG CTC TAT GGG AA-3', and P105R 
5'-TGA GGG CAC AAG AAG CCC CT-3' (8). Hot start PCR reactions were carried out in a 
30 ul volume containing about 50 ng genomic DNA template, 200 uM each dNTP, 200 ng 
each primer, 1.5 raM MgCl2, lx PCR buffer (50 mM KC1, lOmM Tris-HCl pH 8.3) and 1U 
Taq DNA polymerase (Promega, Southampton, UK). After an initial denaturation step of 10 
minutes at 95°C, the samples were processed through 30 temperature cycles of 30s at 94°C, 
30s at 55°C and 30s at 72°C. A final extension step of 72°C for 10 minutes was performed. 
The 176 bp PCR products (20 ul) were digested for two hours at 37°C with 2 units of A/w26I 
(Fermentas Inc, Vilnius, Lithuania). The detection of the different alleles was carried out by 
horizontal ethidium bromide 4% agarose gel electrophoresis, along with a 100-bp DNA 
ladder. 
Methylation analysis 
Patients and tissue sample collection: 
All patients from to the PA group harbored clinically localized prostate adenocarcinoma 
[Tic, according to the TNM staging system (21)], and were consecutively diagnosed and 
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treated with radical prostatectomy. The 43 patients of the PB group were submitted to 
transurethral resection of the prostate (TURP), and carried no histological evidence of 
malignancy. Two pathologists (R.H., C.L.) reviewed all the histological slides and each tumor 
was graded according to the Gleason grading system (22). Fresh tissue, snap-frozen in 
isopentane and stored at -80°C, or paraffin-embedded prostatic tissue was collected from each 
surgical specimen. Sections were cut for the identification of areas of high grade prostatic 
intraepithelial hyperplasia (PIN) and adenocarcinoma (radical prostatectomy specimens), and 
BPH (TURP tissue). These areas were then carefully micro-dissected from 12-^m thick 
sections for enrichment of PIN, adenocarcinoma and hyperplastic tissue. An average of 50 
sections for each area with enrichment (>70%) in neoplastic cells were used for DNA 
extraction of PIN or cancer. Paraffin-embedded tissue was similarly micro-dissected, but was 
placed in xylene for 3 hours at 48 °C to remove the paraffin. DNA was extracted using the 
method described by Ahrent et al. (20). 
Bisulfite Treatment: 
Sodium bisulfite conversion of 2 ug of genomic DNA was performed by a modification of 
a previously described method (23). Briefly, NaOH was added to denature DNA (final 
concentration 0.2 M) and incubated for 20 minutes at 50 °C. A volume of 500 \i\ freshly made 
bisulfite solution (2.5 M sodium metabisulfite and 125 mM hydroquinone, pH = 5.0) was 
added to each sample and incubation was continued at 50° C for 3 hours in the dark. Modified 
DNA was purified using the Wizard DNA purification resin according to the manufacturer 
(Promega Corp., Madison, WI) and eluted in 45 u.1 of water at 80 °C. After treatment with 
NaOH (final concentration, 0.3 M) for 10 minutes at 37 °C, isolation was continued with 75 ul 
7.5 M ammonium acetate followed by an incubation step of 5 minutes at room temperature. 
Finally, the modified DNA was precipitated by adding 2.5 volumes of 100% ethanol and 2 |il 
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glycogen (5 mg/ml). The pellet was washed with 70% ethanol, dried, and eluted in 30 ^1 5 
mM Tris (pH 8.0). 
MSP analysis: 
For PCR amplification, 2ul of bisulfite-modified DNA was added in a final volume of 25(xl 
PCR mix containing IX PCR buffer (16.6 mM ammonium sulfate/67mM Tris, pH8.8/6.7mM 
MgCl2/10 mM 2-mercaptoethanol), dNTPs (each at 1.25mM), 1U Platinum Taq DNA 
polymerase (Life Technologies, Inc., Rockville, MD) and primers (300 ng each per reaction). 
Primer sequences for either methylated or modified unmethylated GSTP1 have been described 
previously (24). MSP was carried out using the following conditions: 1 cycle at 95°C for 1 
min; 35 cycles of 1 min 95°C, 1 min 62°C, and 1 min 72°C and a final extension for 5 min at 
70°C. In each performed PCR, treated DNA extracted from two prostate cancer cell lines, the 
LNCaP and Du 145 were used as positive and negative controls, respectively. The PCR 
products were directly loaded onto a non-denaturing 6% polyacrylamide gel, stained with 
ethidium bromide, and visualized under UV illumination. 
Immunohistochemical analysis 
Four urn sections were cut and placed in aminopropyltriethoxysilane (Sigma, No. A-
3648) coated slides. After dewaxing the sections, endogenous peroxidase activity was 
inhibited with freshly prepared 0.5% hydrogen peroxide in distilled water for 20 minutes. 
Then, they were processed in a 600 W microwave oven, at maximun power, three times for 2 
minutes, each time in citrate buffer (pH=6). Immunostaining was performed using an 
immunoperoxidase method according to manufacturer's instructions (Vectastain ABC Kit, 
Vector Laboratories, CA, USA). The incubation of the primary anti-GSTn antibody (clone 3 
BD-Transduction Laboratories, Lexington, KY) was performed overnight at 4° C, at a dilution 
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of 1:250 in 1% BSA in phosphate buffer saline (PBS). Sections were developed with a 
peroxidase substrate solution (0.05% 3,3-diaminobenzidine tetrahydrocloride, 0.01% H202 in 
PBS), counterstained with hematoxylin, dehydrated and mounted. Appropriate positive 
controls were used for each antibody, and negative controls consisted of the replacement of 
the primary antibody for 1% BSA in PBS. 
Assessment of GSTTC expression was performed by light microscopy at x400 
magnification. The presence or absence of immunostaining was evaluated in morphologically 
normal areas, PIN lesions, and tumor, as well as in BPH samples. 
Statistical Analysis: 
The odds ratio (OR) and 95% confidence intervals (CI) were calculated as a measure 
of the association between GSTP1 genotype and the risk of development of prostate cancer. 
Association between GSTP1 genotype and methylation status, as well as the correlation 
between GSTP1 methylation and GSTTI expression were examined using the chi-square test, 
and Fisher's exact test, when appropriate. Analyses were conducted using a computer-assisted 
program - Epi Info, version 6 (Centers for Disease Control and Prevention, Atlanta, GA). 
Statistical significance was considered when P<0.05. 
RESULTS 
Population characteristics and distribution of GSTP1 genotypes 
The median age was 63 years (range: 48-74), 65.5 years (range: 53-82), and 53 years 
(range: 45-64), for PA, PB and PC groups, respectively. The age distribution of the PC group 
differed significantly from the age distribution of the PA and PB groups (p<0.0001). No 
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statistically significant difference was found between the age distribution of the PA and PB 
groups (p=0.08). 
Table 1 depicts the frequency distribution of each GSTP1 genotype (Fig. 1) among the 
3 groups considered for this study, and no statistically significant difference was found 
(p=0.40). No significant effect on prostate cancer risk was detectable for GSTP1 genotype 
(OR=1.13, 95% CI=0.62-2.06), comparing to the blood donors control population (PC). When 
the risk for prostate cancer was assessed using the PB group as control population, no 
significant effect of GSTP1 was detected, as well (OR=0.79, 95% CI=0.35-1.75). 
Methylation analysis 
Methyl specific PCR identified 89 of 105 (84.8%) adenocarcinomas and 17 of 34 
(50%) paired high grade PIN lesions as positive for GSTP1 methylation (Fig. 2). Moreover, 9 
of 43 (20.9%) patients with BPH also displayed GSTP1 methylation. 
No statistically significant association was found between GSTP1 genotype and tumor 
methylation status (P=0.64). The same trend was observed when GSTP1 genotype and BPH 
methylation status were analyzed (P=0.71). 
Immunohistochemical analysis 
In normal and hyperplastic tissue, GSTP1 immunoreactivity was always present in 
basal cells. This staining was mainly cytoplasmic but nuclear staining was also a frequent 
finding. Luminal secretory cells displayed much weaker staining than basal cells. No 
difference in immunostaining was observed between BPH cases with or without GSTPl 
hypermethylation. 
Tumors expressing GSTrc showed cytoplasmic but not nuclear staining. The same was 
observed in dysplastic luminal cells of PIN lesions. Of the 99 tumors that lacked GSTTI 
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expression, 89 (89.9%) displayed GSTP1 promotor hypermethylation, whereas none of the 6 
tumors that expressed GST;t was methylated at the GSTP1 locus (Fisher's exact test: 
P<0.00001). Concerning PIN lesions, cytoplasmic staining was observed in 7 of 34 (20.6%) 
cases, and five of these cases showed GSTP1 hypermethylation. Regarding the negative PIN 
lesions (27 cases), 15 were methylated and 12 unmethylated. Fisher's exact test did not 
disclose significant differences (P=0.67). 
DISCUSSION 
Although there is an increasing body of evidence which suggests an association 
between I105V polymorphism at the GSTP1 locus and cancer susceptibility, namely in 
bladder, testicular, breast and lung neoplasms (6, 18, 25), the influence of this same 
polymorphism in prostate cancer risk remains controversial (8-12). 
In the present study no evidence of a differential risk for prostate adenocarcinoma 
among men possessing the isoleucine or valine variants of codon 105 of GSTP1 was found. 
This result is in accordance with most previously published studies (9-11), but is in 
disagreement with the recent report of Gsur and co-workers (12). However, a major difference 
between our study and theirs is the control population. Gsur et al. used 166 age-matched 
control patients with BPH and we used both a group of BPH patients and a group of healthy 
blood donors. Here, the observed difference in age distribution between the blood donors and 
the cancer patients could be potentially problematic due to the latency of prostate cancer. The 
inclusion of a group of BPH patients (PB) partially overcomes this problem, and no difference 
in GSTP1 genotype frequencies between this group and prostate cancer patients was found 
either. 
GSTP1 promoter hypermethylation is a frequent alteration in prostate cancer cells and 
is associated with gene silencing and decreased GSTTC expression (15, 16). Thus, we 
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hypothesized that this epigenetic modification could overcome the difference in enzyme 
activity caused by the I105V polymorphism, unless the polymorphism would influence GSTP1 
promoter methylation status. MSP analysis of GSTP1 promoter hypermethylation in prostate 
adenocarcinoma tissue samples obtained from the PA group disclosed a high percentage of 
methylated tumors (84.9%), which is in accordance with previously published results (13, 14, 
18, 19). Moreover, no association was found between GSTP1 hypermethylation and GSTP1 
genotype. This is an expected result since the A to G substitution (I105V polymorphism) 
occurs at position 1578 (exon 5) and GSTP1 hypermethylation associated with prostate cancer 
takes place at the gene promoter region (5-7, 16). Indeed, exon 5 is enriched in methylated 
CpG sites even in normal tissue (16) and thus it would be unsound that the A to G substitution 
in such a dowstream position would have implications in promoter methylation status. 
To confirm the regulation of GSTP1 promoter hypermethylation in GSTTC expression 
we performed an immunohistochemical analysis in the radical prostatectomy and TURP 
specimens from our patients. The immunohistochemical findings confirm that GSTP1 
promoter hypermethylation is related with the loss of GSTTC expression in prostate cancer, 
since all methylated tumors lacked GSTTE. Previous studies reached the same conclusion (15, 
16) and similar findings were also reported in breast cancer (24). However, a novel finding 
from our study is the lack of GSTTC expression in 10 primary tumors not displaying GSTP1 
methylation. Thus, it is suggested that alternative mechanisms for GSTP1 transcription 
inactivation might occur besides promoter hypermethylation. Interestingly, even prostate 
cancer cells displaying GSTTC immunoreactivity may lack enzyme activity (16). Moreover, 
loss of expression of GSTTC associated with GSTP1 promoter methylation was found even in 
precursor lesions such as PIN (15). Hence, GSTTU loss of expression appears to play a critical 
role in early steps of prostate carcinogenesis. 
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For this reason, we also analyzed 34 PIN lesions form the radical prostatectomy 
specimens. GSTP1 hypermethylation has been reported in 50-70% of PIN lesions (15, 19), and 
other researchers were unable to detect GSTTC expression in this pre-neoplastic condition (26). 
We found immunoreactivity for GSTTC in 7 of 34 cases, from which five were methylated at 
GSTP1 promoter region. This result may be related to the difference in GSTP1 methylation 
levels found between PIN and adenocarcinoma (19). In this respect, it is noteworthy that all 
methylated BPH lesions herein analyzed, expressed GSTTI and these lesions also displayed a 
significantly lower level of GSTP1 methylation (19). These findings favor the existence of a 
critical level of methylation for the silencing of the GSTP1 transcription. 
In conclusion, our results confirm that GSTP1 promoter hypermethylation is a highly 
prevalent event in prostate cancer (already observed in precursor lesions) and is linked to 
GSTTC loss of expression. Moreover, I105V GSTP1 polymorphism is not associated with 
hypermethylation in the promoter region nor it seems to be related with altered susceptibility 
to prostate cancer. These findings suggest that GSTP1 epigenotype overcome GSTP1 genotype 
in determining GSTTC function. 
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Table I - Genotype frequency distribution in prostate cancer patients (PA), patients with benign 
prostatic hyperplasia (PB), and healthy blood donors (PC). 
Genotype frequency PA(n=105) PB (n = 43) 
16 (37.2%) 
PC (n - 98) 
GSTP1*AI*A 45 (42.9%) 45 (45.9%) 
GSTP1*AI*B 44(41.9%) 24 (55.8%) 43 (43.9%) 
GSTP1*BI*B 16 (15.2%) 3 (7.0%) 10(10.2%) 
Fig. 1- PCR-RFLP analysis of the GSTP1 lie-105-»-Val polymorphism. The consensus 
sequence corresponding to GSTP1*A allele was not cut, but the Val sequence corresponding 
to GSTP1*B was cleaved to yield two fragments, of 91 and 85 bp. Homozygous wild-type 
(*A/*A), hétérozygote (*A/*B) and homozygous mutant (*B/*B) cases are depicted in lanes 2-
4, respectively. The 100 bp DNA ladder is shown in lane 1, and the water control in lane 5. 
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#54 #90 
II 1 
MN T MN T M+ U+ 
Fig. 2- Illustrative example of MSP for GSTP1 promoter region in prostate tissues from non-
neoplastic areas (MN), and clinically localized prostate adenocarcinoma (T) of patients #54 
and #90. Lanes U and M correspond to unmethylated (97 bp) and methylated (93 bp) 
reactions, respectively. In each case, DNA from normal lymphocytes was used as negative 
control for methylation (U+), DNA from LNCaP cell line was used as positive control for 
methylation (M+), and water was used as negative PCR control (H20). On the right side, the 
100 bp DNA ladder is depicted. 
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ABSTRACT 
DNA hypermethylation analysis can be a useful marker for the early detection of cancer 
cells. Using prospectively collected tissue samples from patients harboring clinically 
localized prostate cancer, and a control group of patients with benign prostatic hyperplasia 
(BPH), we investigated the potential use of endothelin B receptor (ENDRB) hypermethylation 
as a prostate cancer specific marker. By MSP analysis 83.3% of cases were methylated both 
in tumor and normal tissue of prostate cancer patients as well as 91.3% of BPH samples. We 
concluded that EDNRB hypermethylation at CpG sites upstream the transcription start site 
does not distinguish normal from neoplastic prostate cells, thus precluding a role as prostate 
cancer marker. 
Key words: ENDRB, hypermethylation, prostate, HBP. 
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1. INTRODUCTION 
Prostate adenocarcinoma is the second leading cause of cancer related death in men from 
North America and Western Europe [1]. Indeed, at current rates of diagnosis, a man in the 
USA has a one-in-five chance to develop invasive prostate cancer during his lifetime [1]. 
Whereas organ-confined prostate adenocarcinoma (PA) can be cured in the majority of 
patients, the treatment of more extensive tumors has met with limited success. Thus, the 
development of new and reliable methods devised for early detection of localized tumors 
elevates the likelihood of cure after radical therapy, and may have strong implications in 
patient outcome [2]. 
CpG islands are 1 kb-length regions often associated with promoters or transcribed 
exons of genes [3]. These islands normally remain unmethylated in the germ line and in 
normal adult tissue [4], and rarely become methylated in somatic cells [5]. Moreover, 
methylation of cytosines at CpG islands has been recently recognized as an important 
epigenetic alteration, that may play a decisive role in the control of gene expression, namely 
during mammalian development [6]. Alterations in the methylation patterns of promoter CpG 
islands has been associated with transcriptional inhibition of genes in many human cancers 
and stands as an alternative mechanism of gene inactivation [7-9]. Examples of genes that are 
frequent targets for de novo methylation include pl6, pi5, RBI, GSTP1, the estrogen receptor 
gene (ESR1), and the DNA repair genes such as MLH1, and MGMT [10-17]. Moreover, these 
epigenetic alterations have been proposed as molecular markers for the detection of several 
tumors, namely in prostate cancer [18-21]. Indeed, pi6 methylation was reported in three of 
five prostate cancer cell lines analyzed, although this alteration was found to be less common 
in prostate primary tumors (13%) [25]. Studies on E-cadherin and CD44 also yielded low 
frequency of promoter hypermethylation in prostate cancer [26, 27]. On the contrary, GSTP1 
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was found to be frequently methylated in this neoplasm (-90% of cases) but additional 
molecular markers should be sought to further increase the detection rate [20, 21, 32, 33]. 
The endothelin B receptor (ENDRB) gene is located on chromosome 13 and its role in 
carcinogenesis is still unknown, although recent findings suggest that EDNRB signaling is 
necessary during embriogenesis [25, 26]. Therefore, the EDNRB gene joins a growing number 
of genes that are of importance in normal development and may become disregulated in 
cancer [27]. Previous studies have shown that EDNRB gene is abnormally methylated in a 
high percentage of prostate tumors [25, 26], and that no methylation was found in normal 
tissues [28]. Thus, a potential use of this marker in the molecular detection of prostate cancer 
can be envisaged. 
Hence, to test the usefulness of the detection of ENDRB somatic methylation as a 
prostate cancer marker, we analyzed the methylation status of the promoter region of this 
gene in a series of 48 adenocarcinomas and morphologically normal tissue collected from the 
same patients. For control purposes, tissue from patients with benign prostatic hiperplasia 
(BPH) was also analyzed. 
2. MATERIALS AND METHODS 
2.1. Patients and Sample Collection 
Forty-eight patients with clinically localized prostate adenocarcinoma, consecutively 
diagnosed and primarily treated with radical prostatectomy at the Portuguese Cancer Institute 
- Porto, were selected for this study. All cases were identified by raised serum PSA in routine 
analysis and confirmed by sextant prostate biopsy (stage Tic). Additionally, 23 patients with 
BPH, submitted to transurethral resection of the prostate (TURP), were included for control 
purposes. Fresh prostatic tissue was collected from each surgical specimen, snaped-frozen in 
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isopentane and stored at -80°C. Sections were cut for the identification of areas of 
morphologically normal tissue and adenocarcinoma (radical prostatectomy specimens), and 
BPH (TURP specimens). These areas were then carefully micro-dissected from 12-|im thick 
sections for cell enrichment. DNA was extracted from either hyperplastic or tumor tissue 
collected from each patient, according to the method described by Ahrent et al. Briefly, DNA 
was digested overnight at 48°C with proteinase K (0.5mg/ml) in 1 % SDS, Tris (1M, pH8.8) 
and EDTA (0.5M, pH8.0) and NaCl (5M), followed by phenol/chloroform extraction and 
ethanol precipitation [27]. 
2.2. Bisulfite Treatment 
Sodium bisulfite conversion of 2 ug of genomic DNA was performed by a modification of a 
previously described method [31]. In brief, DNA was denatured in 0.2M NaOH for 20 min at 
50°C. A volume of 500 |il freshly made solution containing 2.5 M sodium bisulfite (Sigma) 
and 125 mM hydroquinone (Sigma) at pH 5.0) was added to each sample and incubation was 
continued at 50° C in the dark. After 3 hours of incubation, the modified DNA was desalted 
through a column (Wizard DNA purification resin, Promega Corp., Madison, WI), according 
to the manufacturer instructions. After treatment with NaOH (final concentration, 0.3 M) for 
10 minutes at 37 °C, isolation was continued with 75 JLLI 7.5 M ammonium acetate followed 
by an incubation step of 5 minutes at room temperature. Finally, the modified DNA was 
precipitated with 2.5 volumes of 100% ethanol and 2 jul glycogen (5 mg/ml). The pellet was 
washed with 70% ethanol, dried, and eluted in 30 u,l 5 mM Tris (pH 8.0). 
2.3. MSP analysis 
For PCR amplification, 2(J,1 of bisulfite-modified DNA was added in a final volume of 25|il 
PCR mix containing IX PCR buffer (16.6 mM ammonium sulfate/67mM Tris, pH8.8/6.7mM 
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MgCl2/10 mM 2-mercaptoethanol), dNTPs (each at 1.25mM) and primers (300 ng each per 
reaction). The primers sequences were: 5'-TGGTGAAGAGGTTGTGGGTGGTA 
TTAGTG-3' (sense) and 5'-ACCTACTCCAAAAACATCCAATAACCA-3' (anti-sense) for 
unmethylated DNA and 5'-CGAAGA GGTTGCGGGCGGTATTAGCG-3' (sense) and 5'-
TACTCC AAAAACGTCCGATAACCG-3' (anti-sense) for methylated DNA. Considering 
the nucleotide positions are numbered relative to transcription start site (+1), the PCR-
amplified region for methylated alleles spanned from -139 to -9 , and for unmethylated alleles 
spanned from -141 to -7. This region contains 9 CpG dinucleotides, including 6 CpG at the 
primer annealing sites. PCR was performed using the following conditions: 1 cycle at 95°C 
for 1 min; 35 cycles of 1 min 95°C, 1 min 62°C, and 1 min 72°C and a final extension for 5 
min at 70°C. In each performed PCR, treated DNA extracted from a prostate cancer cell line 
(PC3) and from normal lymphocytes, was used for positive and negative control purposes, 
respectively. The PCR products were directly loaded onto a non-denaturing 6% 
polyacrylamide gel, stained with ethidium bromide, and visualized under UV illumination. 
3. RESULTS AND DISCUSSION 
DNA hypermethylation in neoplastic tissue, comparatively to the normal tissue counterpart, 
has been described in many instances and it has been suggested that these changes could be 
useful markers for the early detection of cancer cells [18-21]. Concerning prostate cancer, a 
promising marker has been found, i.e., GSTP1 hypermethylation, which can be detected both 
in tissue and bodily fluids [14, 20, 21, 32, 33]. Since GSTP1 hypermethylation is present in 
-90% of prostate adenocarcinomas, additional molecular markers should be sought to further 
increase the detection rate [20, 21, 32, 33]. A previous study by Nelson et al. has shown that 
the EDNRB gene is abnormally methylated in -70 % of prostate tumors, and no methylation 
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was found in normal tissues [28]. Thus, we hypothezised that EDNRB hypermethylation 
could potentially be used as an additional molecular marker for prostate cancer. 
In our study, MSP analysis of the 5'region of the EDNRB gene located at the fringe of 
the CpG island according to Pao et al. [29], showed that 40 of 48 (83.3%) cases were 
methylated both in tumor and normal prostate tissue obtained from patients with 
adenocarcinoma. The remaining 8 (16.7%) cases were unmethylated both in the tumor and 
the normal tissue samples. Moreover, we found that only 2 (8.7%) cases of BPH were not 
methylated at the same CpG sites. The primer sets used in this study included two CpG sites 
(-130 and -8) analyzed in the forementioned report [26]. Our results are in accordance with 
that previous study which showed CpG -130 methylation in prostate adenocarcinoma and 
normal adjacent tissue, although in the latter the levels of methylation were generally lower, 
as expected for normal tissues [29]. However, since conventional MSP was used in our study, 
no conclusions can be drawn regarding the methylation levels. 
The region of the EDNRB gene promotor analyzed in our study, was chosen 
considering a previous study that indicated the 3'-most CpG dinucleotide analysed therein as 
more heavily methylated than the 5' end [28]. Our results confirm this finding concerning the 
methylation status of adenocarcinoma samples. However, due to the high sensitivity (1:1000) 
of the MSP method used in the present study [34], we were also able to detect DNA 
hypermethylation in paired normal tissue and hyperplastic tissue from the control group 
(BPH). Moreover, the increased sensitivity of the method may explain the larger proportion 
of methylated tumors found in the present study. These findings are consistent with the results 
recently reported by Pao et al., that found EDNRB methylation levels varying from 11 to 25% 
in all the 5 normal samples analyzed, and varying from 11 to >50% in the paired prostate 
tumors [29]. Thus, EDNRB methylation at these CpG sites does seem to be a useful marker 
for detection of prostate cancer. Indeed, Pao et al. have shown that selected CpG sites located 
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more downstream in the CpG island of the EDNRB gene may be more reliable markers for 
malignancy [29]. 
The finding that the EDNRB methylation status at these CpG sites in prostate 
adenocarcinoma cases parallels the respective normal tissue does not seem to support an 
important role for this epigenetic alteration in prostate carcinogenesis, as previously 
anticipated [28]. However, these frequently methylated sites may play an important role as 
starting points for methylation in more downstream CpG sites which are frequently 
methylated in prostate tumors but not in normal tissue [29]. In this regard, the analysis of 
these more downstream sites in the cases found to be unmethylated in our study could 
contribute to test this hypothesis. 
In conclusion, the detection of EDNRB gene hypermethylation at CpG sites upstream 
to the transcription start site does not allow for the distinction between normal and neoplastic 
prostate cells, thus preventing its use as a prostate cancer marker. However, further analyzes 
of more downstream sites in a large series of patients may unravel a role for EDNRB gene 
methylation in prostate cancer detection. 
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#26 
Fig. 1 Illustrative example of MSP for ENDRB promoter region: morphologically normal 
(MN) tumor (T) of patients #4 and #26. Lanes U and M correspond to unmethylated (134 bp) 
and methylated (130 bp) reactions, respectively. In each case, normal lymphocytes DNA was 
used as negative control for methylation (U+), DNA from PC3 cell line was used as positive 
control for methylation (M+), and water was used as negative PCR control (H20). On the 
right side the HiLo marker is depicted. 
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ABSTRACT 
We recently demonstrated the existence of specific patterns of somatic mitochondrial 
DNA (mtDNA) mutations in several cancers. Here we sought to identify the presence of 
mtDNA mutations in prostate cancer and their paired PIN lesions. The D-loop region, 16S 
rRNA, and the NADH subunits of complex I were sequenced to identify mtDNA mutations in 
16 matched PIN lesions and primary prostate cancers. Twenty mtDNA mutations were 
detected in the tumor tissue of three patients. Identical mutations were also identified in the 
PIN lesion from one patient. This patient with multiple point mutations also harbored a high 
frequency of microsatellite instability (MSI-H) in nuclear mononucleotide repeat markers. 
Remarkably, these mutations were also detected in all (3/3) matched urine and plasma 
samples obtained from these patients. Although mitochondrial mutations are less common in 
prostate adenocarcinoma, they occur early in cancer progression and they can be detected in 
bodily fluids of early stage disease patients. The identification of MtDNA mutations may 
complement other early detection approaches for prostate cancer. 
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INTRODUCTION 
Prostate cancer is the most commonly diagnosed cancer among men in most Western 
countries and a leading cause of cancer-related mortality in the USA. (Landis et al, 1999) 
Surgery remains one of the most effective treatment modalities for this disease. Since the 
likelihood of cure relies mainly in the early detection of the tumor (i.e., while still confined 
within the prostatic capsule), the development of novel and more effective detection 
techniques for early-stage prostate cancer is becoming increasingly important. 
A number of genes have been found to be mutated in prostate cancer. However, these 
alterations have been consistently found either just in a small number of cases, including ras 
oncogenic activation and TP53 inactivation (Isaacs and Isaacs, 1996), or predominantly in 
advanced disease, such as PTEN inactivation. (Cairns et al, 1997) Thus, one major challenge 
is to identify more frequent genetic alterations in early stages of the disease, and in 
premalignant lesions like prostate intraepithelial neoplasia (PEN), to allow DNA-based 
detection of this major tumor type. (Isaacs and Isaacs, 1996) 
Recently, we as well as others have demonstrated the existence of specific mutation 
patterns in the mtDNA of various cancers. (Fliss et al, 2000; Polyak et al, 1998) In some 
cases these mutations may lead to abnormal metabolic and apoptotic processes in neoplastic 
cells. (Green and Reed, 1998) Indeed, mutational hot spots within protein-coding regions, 
namely in the NADH dehydrogenase subunits 3, 4 and 5 from complex I, were identified in 
colorectal and renal tumors. (Polyak et al, 1998; Horton et al, 1996) Furthermore, the non-
coding displacement-loop region (D-loop) was found to be a mutational hot spot in bladder, 
lung, and head and neck neoplasms. (Fliss et al, 2000) Mutations in this region may be 
related to the function of the D-loop as a regulatory site for both replication and expression of 
the mt genome. (Fliss et al, 2000) Interestingly, most of the mtDNA mutations were shown 
to be homoplasmic and could be readily detected in paired bodily fluids obtained from 
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affected patients. (Fliss et al, 2000) The present study was undertaken to determine whether 
mitochondrial mutations could be detected in prostatic adenocarcinoma, paired PIN lesions, 
voided urine specimens, and plasma samples. We thus, sequenced the D-loop region, 16S 
rRNA and Complex I in these primary tumors and identified 20 mtDNA mutations in 3 
prostate cancers and one matched PIN lesion. Subsequently we detected mutant mtDNA in 
the urine and plasma of these affected patients. 
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RESULTS AND DISCUSSION 
We sequenced the mtDNA D-loop region and NADH dehydrogenase in 16 matched 
PIN lesions, primary prostate tumor, and the corresponding paired lymphocytes (Figure 1). 
We found 20 somatic mutations, detected in three of the 16 patients examined (Table 1). All 
the somatic mutations detected were homoplasmic or near homoplasmic (Figure 1), 
confirming results from previous studies, in which the mutated mtDNA became the dominant 
population in tumor cells. (Fliss et al, 2000; Polyak et al, 1998) In addition, 96 
polymorphisms were identified of which 27 were not previously described (Table 2). 
(Andrew et al, 1999) We amplified relatively large PCR products (2.5-3.2 kb), in order to 
avoid amplification of nuclear encoded pseudogenes. (Parfait et al, 1998) All the primer sets 
used in this study produced no PCR products in a cell line without mtDNA. We also applied a 
more sensitive oligonucleotide mismatch ligation assay to confirm mutated sequences in 
tumor DNA, and a negative signal was always found in the matched lymphocyte DNA (see 
below). 
The excessive exposure of mtDNA to reactive oxygen species (ROS), generated 
during OXPHOS, results in extensive oxidative damage consistent with T-to-C and G-to-A 
mutations. (Cadet et al, 1997) In our study, only 9 out of the 20 mutations identified (45%) 
were T-to-C and G-to-A base transitions, potentially indicating less exposure to ROS-derived 
mutagens in this type of tumor. However, one patients tumor harbored most of the observed 
mutations (case #1) probably biasing the mutation distribution. This patient presented 
multiple mutations widely distributed across various mitochondrial regions, suggesting the 
possible accumulation of mtDNA damage during tumorigenesis from endogenous factors 
(Fig. 1A). Alternatively, these multiple mutations are the result of a limited but catastrophic 
mutagenic effect from a severe exogenous exposure. (Croteau and Bohr, 1997) Intriguingly, 
this patient worked for many years at a chemical plant. 
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It has been previously shown that mtDNA instability may be correlated with nuclear 
genome instability, thereby suggesting that deficiencies in mismatch repair genes may also 
affect mtDNA. (Habano et al, 1998) Since repeat sequence instability has been described in 
the mtDNA of patients with putative mismatch repair deficiency, we evaluated the status of 
the nuclear genome in patient #1, analyzing several common mononucleotide repeat markers 
(BAT-25, BAT-26, BAT-34C4 and BAT-40). We found allelic size variation (microsatellite 
instability) for BAT-25 and BAT-26 in the PIN lesion and paired adenocarcinoma DNA (data 
not shown) suggesting an impairment of the mismatch repair system. Because one tumor 
(patient #46) harbored a A-tract one base pair deletion, the status of the nuclear genome in 
this patient was also analyzed with the same common mononucleotide repeat markers but no 
evidence of widespread genetic instability was found (data not shown). 
In the patient with multiple tumor mutations all of the mutations found in the primary 
tumor sample were also detected in the PIN lesion, providing further evidence for the 
precursor nature of PIN in relation to prostatic adenocarcinoma. Since all the mutations were 
already present in the PIN lesion, the mtDNA alterations are likely to be an early event in 
prostatic carcinogenesis. However, in the other cases we did not detect identical mtDNA 
mutations in the respective PIN lesion (Fig. IB and 1C). Although favoring mtDNA mutations 
later in cancer progression, this result could be explained by the heterogeneity that 
characterizes both prostate adenocarcinoma and PIN. Indeed, prior studies using 
microsatellite allelic imbalance analysis demonstrated the heterogeneous nature of multiple 
foci of PIN and prostate carcinoma, within the same prostate. (Bostwick et al, 1998) These 
findings are suggestive of the presence of multiple clonal PIN lesions characterized by 
different genetic abnormalities, eventually leading to genetically unrelated foci of 
adenocarcinoma. 
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Tumor specific molecular abnormalities can be detected in many bodily fluids and 
have been investigated as a diagnostic tool in several tumor types. (Sidransky, 1997) We 
tested paired bodily fluids and found that mutant mtDNA could be detected in the urine and 
plasma samples from all three patients that harbored mutated mtDNA in the primary tumors 
(Fig. 2). This result is supported by the homoplasmic nature of the somatic mutations detected 
in the primary tumor, providing an unprecedented detection advantage due to the high copy 
number of mutant mtDNA in neoplastic tissue. (Fliss et al, 2000; Polyak et al, 1998; 
Wallace étal, 1999) 
However, the mutated mtDNA was still clearly dilute in all paired urine and plasma 
samples (Figure 2 and data not shown) suggesting that very little neoplastic DNA is shed 
(and/or survives) from the prostatic epithelium to the urine or blood, at least in early stage 
prostatic adenocarcinoma. This observation is supported by our recent study suggesting that a 
nuclear molecular target (hypermethylation of GSTP1), is also challenging to detect paired 
serum and urine from prostate cancer patients. (Cairns, et al, 2000) These results also stand 
in stark contrast to the ease of urine detection for bladder cancer based on microsatellite DNA 
analysis. (Mao etal, 1996; Steiner et al, 1997) 
We have found that mtDNA mutations are a relatively rare event in prostate cancer. In 
at least one case, identical mtDNA mutations were found in a precursor PIN lesion suggesting 
that mtDNA mutations can occur early in the neoplastic process. Although limited by their 
low prevalence in prostate cancer, mtDNA mutations identified in primary tumors may aid as 
sensitive markers for detection of residual tumor burden or minimal disease, after primary 
cancer resection. 
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MATERIALS AND METHODS 
Sixteen patients with clinically localized prostate adenocarcinoma (stage Tic), 
consecutively diagnosed and treated with radical prostatectomy at the Portuguese Cancer 
Institute were selected for this study. From each patient, fresh prostatic tissue was collected 
and snap-frozen in isopentane, immediately after resection and in an orderly fashion, enabling 
topographic correlation with the tissue submitted for routine processing (formalin fixation and 
paraffin embedding). Frozen sections were subjected to light microscopy observation after 
haematoxylin-eosin staining by two pathologists. Areas of benign epithelium, PIN and 
adenocarcinoma were identified and carefully microdissected from 12-̂ im thick sections. An 
average of 50 sections for each area was used. From samples of peripheral blood, plasma was 
separated, and lymphocytes were collected and used as source of normal DNA. Samples of 
voided urine were also obtained. DNA was extracted from all the samples (tissue, 
lymphocytes, plasma, and urine) as previously described. Briefly, DNA was digested 
overnight at 48°C in 1% SDS/Proteinase K (0.5mg/ml), extracted by phenol-chloroform, and 
ethanol precipitated. (Ahrendt et ai, 1999) 
In order to avoid possible contamination from nuclear-encoded pseudogenes, 
fragments with more than 2.5 kb in length containing the D-loop region, 16S rRNA, and the 
NADH dehydrogenase subunits (from ND1 to ND6), were amplified using the overlapping 
primers designed by Polyak et al. (Polyak et al, 1998) In a PCR buffer containing 6% 
DMSO, approximately 300 ng of genomic DNA was subjected to a step-down PCR protocol: 
94°C 30 sec, 64°C 1 min, 70°C 3 min, 3 cycles, 94°C 30 sec, 61°C 1 min, 70°C 3 min, 3 
cycles, 94°C 30 sec, 58°C 1 min, 70°C 3.5 min, 15 cycles, 94°C 30 sec, 57°C 1 min, 70°C 3.5 
min, 15 cycles, and a final extension at 70 °C for 5 min. PCR products were gel-purified using 
a Qiagen gel extraction Kit (Qiagen Inc., Valencia, CA) and sequenced using a (y-33P) ATP 5' 
end-labeled sequencing primer and the AmpliCycle sequencing kit (Perkin-Elmer, Roche 
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Molecular Systems Inc., Brachburg, NJ), under the following cycle conditions: 95°C 30 sec, 
52°C 1 min, 70°C 1 min for 30 cycles. The sequenced products were analyzed on a denatured 
6% polyacrylamide gel. In each experiment, DNA extracted from a mtDNA-negative 
osteosarcoma-derived cell line was included, as a negative control. 
Owing to the low concentration of DNA in the urine and plasma samples, mtDNA 
mutations were not detected using sequence analysis alone. Thus, a more sensitive 
oligonucleotide mismatch ligation assay was performed, as described by Jen et al. (1994) In 
short, fragments containing mutations were PCR-amplified using standard conditions and 
ethanol precipitated. For each mutation, discriminating oligonucleotides that contained the 
mutated base at their 3' end were designed (position: 12414, 5'-TTTTGTTG-3' for patient #1, 
position: 2923, 5'-GGAACAAA-3' for patient #32, and position: 11032, 5'-CACGAAAAAA-
3' for patient #46). An immediately adjacent 3' oligonucleotide linker, along with the 
discriminating oligonucleotide (5'-GGGTTAACGAG-3' for patient #1, 5'-TTACCCTAGGG-
3' for patient #32 (5'-AACAATTACCC-3'), and 5'-CTCTACCT-3' for patient #46) were used 
as substrate for the ligation reaction. In addition a blocking oligo was used for the ligation 
reaction in samples from patient #32. Discriminating oligonucleotides (40 ng) were mixed 
with the PCR reaction mixture and 40 ng of the [32P] end-labeled 3' oligonucleotide linker. 
The reactions were incubated at 37°C for 1 hour, in the presence of T4 DNA ligase (Life 
Technologies, Long Island, NY), analyzed on denatured 12% polyacrylamide gels, and 
processed by autoradiography. 
102 
Carmen Jerónimo - Doctoral Thesis 
Table 1. Summary of mtDNA mutations in prostate cancer. 
Position Gene 
Sequence change 
Patient# DNA (L -» T) Protein 
146 D-loop T->C -
189 D-loop A ^ G -
204 D-loop T->C -
207 D-loop G->A -
235 D-loop A->G -
32 2923 16sRNA G-> A -
3357 ND1 A->G M->M 
3434 ND1 G-»A C->Y 
3480 ND1 G->A K->K 
3505 ND1 A-^G T->A 
46 11032 ND4 Del Ter 
11674 ND4 C->T T->T 
11947 ND4 A->G T->T 
12308 TRNA A H > G -
12372 ND5 A->G L->L 
12414 ND5 T->C P->P 
12705 ND5 C->T I-*l 
14053 ND5 G->A A->T 
16183 D-loop A->G -
16189 D-loop T->C -
L = sequence obtained from lymphocytes, T = mutated sequence in 
tumor. All of the mutations in patient #1 were also identified in the 
paired PIN lesion. 
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Table 2. Summary of new polymorphisms found in prostate cancer. 
Sequence Change 
Patient# Position Gene DNA (L -* T) Proteii 
18 528 D-loop T->C -
16 1700 16sRNA T->C -
45 1721 16sRNA C->T -
44 2335 16sRNA A->G -
42 2416 16sRNA T->C -
44 2442 16sRNA T->C -
42 2789 16sRNA C->T -
1 3357 ND1 G->A M->M 
42 3594 ND1 C->T V->V 
42 4104 ND1 A->G L->L 
30 4216 ND1 T->C Y->H 
30 10750 ND4 A->G N->S 
5 11253 ND4 T->C T->T 
16 12372 ND5 G ^ A L->L 
20 12490 ND5 A->G T->C 
42 12693 ND5 A->G K->K 
44 12777 ND5 A->G V->V 
45 13017 ND5 A->G L->L 
44 13188 ND5 C->T T H > T 
45 13434 ND5 A-^G M->M 
42 13623 ND5 C->T L->L 
42 13650 ND5 C->T P->P 
46 13966 ND5 A->G T->A 
44 14110 ND5 T->C F-H>L 
1 16094 D-loop C->T -
5 16409 D-loop A->G -
30 16306 D-loop C->T -
Identical sequence obtained in lymphocytes, prostatic intraepithelial 
neoplasia , and in tumor. 
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A C G T 
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CASE 32 
A C G T 
L PIN T L PIN T L PIN T L PIN T 
Figure 1. Sequence detection of mutated mtDNA in samples obtained from tumors and PIN 
lesions. The mt mutation was detected by direct sequencing of the DNA obtained from the 
lymphocytes (L), PIN (P), and tumor (T), from patients 1 (A) and 46 (B). (A) The arrows 
indicate, respectively, a single nucleotide change A>G at position 189, T>C at position 204, 
and G>A at 207 in the D-loop region. (B) The arrow points to a one bp deletion detected at 
11032np in the ND4 subunit of mtDNA extracted from the tumor. (C) The arrow indicates a 
single nucleotide change G > A at position 2923 in the 16S rRNA. 
B 
CASE 46 
A C G T 
L PES T L PIN T L PIN T I, PIN T 
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CASEI 
L PIN T U P 1:10 1:100 1:1000 
mm mm mm 
Figure 2. Oligonucleotide-mismatch ligation assay to detect mtDNA mutations in urine and 
plasma. The arrows identify mutated mt sequences at 12414 np (within ND5) in the PIN and 
tumor mtDNA. Weaker and more diluted signals were observed in the paired urine and 
plasma samples. No mutated mtDNA was found in the corresponding lymphocytes used as 
source of normal mtDNA, or normal prostate tissue (data not shown). Lanes 1:10, 1:100, 
1:1000 contain a dilution of tumor DNA with lymphocyte DNA from the same patient. 
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V. MAIN CONCLUSIONS AND FUTURE STUDIES 
The aim of this chapter is to state the more relevant findings of the studies composing this 
Doctoral Thesis, each corresponding to one of the scientific papers included. Thus, they are 
organized in a manner similar to the specific aims of the thesis presented in the first chapter. 
A short account on the future research projects finalizes this chapter. 
1. Quantitation of GSTP1 hypermethylation distinguishes between non-neoplastic 
prostatic tissue and organ confined prostate adenocarcinoma: 
1.1. GSTP1 promoter methylation is an almost ubiquitous finding (present in over 90% of 
cases) in early stage prostate adenocarcinoma and is also detectable in over 50% of 
PIN lesions. 
1.2. Contrarily to previous reports, GSTPJ hypermethylation was detected in BPH (29% 
of cases) and in normal prostate tissue from sextant biopsies (40% of cases), 
although in significantly lower levels than prostate adenocarcinoma. 
1.3. Using a selected cut-off value of 10.0 (converted GSTP1/MYOD1 ratio), quantitation 
of GSTP1 hypermethylation allows for the discrimination between neoplastic and 
non-neoplastic prostate tissue, with a positive predictive value of 100%. 
1.4. Quantitation of GSTP1 hypermethylation is an accurate predictor test of malignancy, 
with a sensitivity of 90.9% and a specificity of 100%, as determined in a small 
preliminary study. 
Thus, quantitation of GSTP1 promoter hypermethylation is promising as an exceptionally 
useful marker for prostate cancer in clinically localized disease 
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2. Detection of Prostate Cancer in Urine by GSTP1 Hypermethylation: 
2.1. GSTP1 hypermethylation was amenable to detection in 27% of urine sediments from 
patients showing this epigenetic alteration in the respective tumor tissue. 
2.2. This test shows absolute specificity since no GSTP1 hypermethylation was found in 
urine DNA from the patients with unmethylated GSTP1 tumor DNA. 
Hence, a sensitive non-invasive molecular test that may indicate the presence of prostate 
cancer in individuals with lesions undetectable by currently existing methods is envisioned. 
3. Quantitative GSTP1 hypermethylation in bodily fluids of prostate cancer patients: 
3.1. Using MSP, GSTP1 hypermethylation may be detected in urine and plasma samples 
in a significant proportion of early stage prostate cancer patients harboring DNA 
methylation in the tissue. 
3.2. Comparatively to real-time quantitative MSP, conventional MSP detected GSTP1 
hypermethylation in a larger number of urine and plasma samples (53.6% vs. 
31.9%). 
3.3. Higher amounts of tumor DNA are present in plasma when compared to urine 
sediment, which is consistent with the known propensity of prostate cancer to 
metastasize hematogeneously. 
3.4. Both MSP methods detected GSTP1 hypermethylation in a single urine sample from 
a BPH patient but all plasma samples from these patients were negative. Interestingly 
the respective prostate tissue was negative for methylation thus raising the question 
as to whether the test was detecting a hidden neoplasm. 
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Conventional MSP is more sensitive than real-time quantitative MSP in the detection of 
GSTP1 promoter methylation in urine and plasma from prostate cancer patients with 
clinically localized disease. Moreover, the simultaneous analysis of both bodily fluids 
increases the detection rate of these methods. 
4. I105V polymorphism and promoter hypermethylation of the GSTP1 gene in prostate 
adenocarcinoma 
4.1. In prostate adenocarcinoma, GSTP1 promoter hypermethylation seems to be an 
effective mechanism of gene silencing, leading to GSTTC loss of expression. 
4.2. In PIN lesions, GSTTC expression may occur despite GSTP1 promoter 
hypermethylation. This finding may be related to the different methylation levels 
found in adenocarcinoma and PIN, as previously described. 
4.3. Lack of GSTTI expression is not always associated with GSTP1 promoter 
hypermethylation and, thus, alternative pathways for altered GSTP1 transcription 
may exist. 
4.4. 1105V GSTP1 polymorphism is not associated with altered susceptibility to prostate 
cancer nor with promoter hypermethylation. 
GSTP1 promoter hypermethylation is strongly associated with GSTTI loss of expression, and 
thus it is suggested that GSTP1 epigenotype overcome GSTP1 genotype in determining GSTTT 
function. This latter finding may be related to the lack of association between I105V GSTP1 
polymorphism and increased risk for prostate cancer development. 
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5. Detection of endothelin B receptor hypermethylation in early stage prostate 
adenocarcinoma 
5.1. MSP analysis detected EDNRB promoter hypermethylation in 83.3% of prostate 
adenocarcinomas and paired normal prostate tissue samples 
5.2. EDNRB promoter hypermethylation was identified in most cases (>90%) of BPH 
The detection of EDNRB gene hypermethylation at CpG sites upstream to the transcription 
start site does not allow for the distinction between normal and neoplastic prostate cells, thus 
preventing its use as a prostate cancer marker. 
6. Mitochondrial mutations in early stage prostate cancer and bodily fluids: 
6.1. Twenty mitochondrial DNA mutations were found in 3 cases of prostate 
adenocarcinoma and identical mutations were found in a precursor PIN lesion 
suggesting that mtDNA mutations can occur early in the neoplastic process. 
6.2. Nine of these 20 mutations were base transitions (T-to-C and G-to-A), potentially 
indicating less exposure to reactive oxygen species-derived mutagens. 
6.3. All mutations were homoplasmic allowing its detection in paired urine and plasma 
samples. 
Mitochondrial DNA mutations are a rare event in prostate cancer, potentially due to a lower 
exposure of mtDNA in prostatic cells to ROS-derived mutagens. Although limited by their 
low prevalence in prostate cancer, mtDNA mutations identified in primary tumors may aid as 
sensitive markers of disease in bodily fluids. 
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Concerning future studies, they will be built upon the most interesting and promising 
results of this Thesis: the GSTP1 promoter methylation status as a prostate cancer marker .The 
usefulness of quantifying GSTP1 methylation levels in morphologically normal sextant 
biopsies from patients with raised serum PSA is a very appealing endeavor. The small 
preliminary study revealed promising results for GSTP1 methylation quantitation as a 
potential ancillary diagnostic tool. These patients with raised PSA level and normal biopsies 
suffer from the expectancy of a delayed cancer diagnosis that may eventually preclude 
effective treatment. We hope that this new approach may identify the subset of patients that 
need more close surveillance. 
However, there is still a gap to be filled concerning the molecular detection of prostate 
cancer. About 10% of cases do not show GSTP1 promoter hypermethylation and thus, are not 
amenable to detection by this marker. Hence, screening for methylation of other loci should 
be undertaken. We aim at defining a methylation genetic profile of prostate cancer that may 
enable the design of a thorough screening test, clinically useful and preferentially using non-
invasive procedures. 
A final achievement would be the identification of subsets of prostate adenocarcinoma 
with different clinical behavior and response to therapy based in genetic and molecular 
analyses of tumor samples obtained from sextant prostate biopsies. The clinical relevance of 
this approach is obvious and would allow for an improved therapeutical strategy in this 
common and lethal malignancy. 
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SUMMARY 
Since prostate cancer is the most common malignancy in men in industrialized 
countries, and its incidence, morbidity and mortality have been increasing in recent years, this 
Thesis was aimed at identifying genetic abnormalities and define methodologies that may 
contribute for the early detection of prostate cancer. 
In the first chapter of the Thesis, the potential of GSTP1 promoter methylation as a 
prostate cancer specific marker was investigated. Firstly, we hypothesized that quantitation of 
GSTP1 methylation by real-time methylation specific PCR (MSP) would allow for a 
distinction between neoplastic and non-neoplastic prostate tissue. Moreover, the feasibility of 
detecting this epigenetic alteration in voided urine was assessed in a preliminary study, and 
then conventional and real-time quantitative MSP analyses were performed to determine the 
clinical usefulness of GSTP1 hypermethylation quantitation as a prostate cancer specific 
marker in bodily fluids (voided urine and plasma). Finally, the relation between GSTP1 
polymorphism and epigenetic alterations linked to GSTrc expression in prostate cancer was 
investigated. 
In the second Chapter, analysis of promotor methylation in the endothelin B receptor gene 
(ENDRB) was performed in an attempt to increase the number of primary tumors amenable 
for screening. 
The objective of the third Chapter of the Thesis was to investigate the frequency of 
mitochondrial mutations in prostatic adenocarcinoma (and paired PIN lesions), both in tissue 
samples and in bodily fluids, and whether these changes could be used as tumor molecular 
markers. 
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1. Quantitation of GSTP1 hypermethylation distinguishes between non-neoplastic 
prostatic tissue and organ confined prostate adenocarcinoma: 
Tissue samples from 69 patients with early stage prostatic adenocarcinoma, 28 PIN 
lesions, and 31 patients with benign prostatic hyperplasia (BPH) were tested for GSTP1 
hypermethylation by quantitative fluorogenic real-time MSP. To further verify the clinical 
applicability of this assay we performed a blinded investigation of prospectively collected 
prostate sextant biopsies of 21 patients with raised serum prostate-specific antigen (PSA) 
levels (11 with histologically identified adenocarcinoma, and 10 with no morphological 
evidence of adenocarcinoma). The median ratios (methylated GSTP1/MYOD1) found in 
resected hyperplastic prostatic tissue, intraepithelial neoplasia, and adenocarcinoma were 0.0, 
1.4, and 250.8, respectively (P < 0.00001). The median GSTP1 methylation ratios found in 
adenocarcinomas and normal prostate tissue in sextant biopsies from the 21 prospective 
patients with high PSA levels also differed significantly (410.6 and 0.0, respectively; P = 
0.0007). We concluded that quantitation of GSTP1 hypermethylation may augment standard 
pathology by accurately discriminating between normal hyperplastic tissue and prostatic 
carcinoma within a small tissue sample. 
2. Detection of Prostate Cancer in Urine by GSTP1 Hypermethylation: 
Matched specimens of primary tumor, peripheral blood lymphocytes (normal control) and 
a simple voided urine were collected from 28 patients with prostate cancer of a clinical stage 
amenable to cure. Genomic DNA was isolated from the samples and the methylation status of 
GSTP1 examined in a blinded manner using MSP. Decoding of the results revealed that 22 of 
28 (79%) prostate tumors were positive for GSTP1 methylation. Remarkably, in 6 of 22 
(27%) cases the corresponding urine sediment DNA was positive for GSTP1 methylation 
indicating the presence of neoplastic DNA in the urine. Furthermore, there was no case where 
a urine sediment DNA harbored methylation when the corresponding tumor was negative. 
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Although we only detected GSTP1 methylation in under a third of voided urine samples, we 
have demonstrated for the first time that molecular diagnosis of prostate neoplasia in urine is 
feasible. 
3. Quantitative GSTP1 hypermethylation in bodily fluids of prostate cancer patients: 
Tissue samples from 69 patients with early stage prostatic adenocarcinoma and 31 
patients with BPH were collected. Matched urine and plasma specimens were obtained 
preoperatively. After sodium-bisulfite treatment, extracted DNA was analyzed for GSTP1 
promoter hypermethylation both by conventional and real-time quantitative MSP. In tissue 
samples, GSTP1 hypermethylation was detected in 63/69 (91.3%) of the cancer patients, and 
9/31 of BPH patients (29%). Conventional MSP detected GSTP1 hyermethylation in a larger 
number of urine and plasma than real-time quantitative MSP (53.6% vs. 31.9%, overall). In 
all positive bodily fluids, the paired tumor was also confirmed to be methylated. GSTP1 
hypermethylation was detected by both MSP methods in only 1 (3.2%) urine sample from a 
BPH patient. Although not quantitative, conventional MSP is currently more sensitive than 
real-time quantitative MSP in the detection of GSTP1 hypermethylation in bodily fluids from 
prostate cancer patients with clinically localized disease. The value of quantitative 
determinations in monitoring and risk assessment remains to be further explored. 
4. 1105V polymorphism and promoter hypermethylation of the GSTP1 gene in prostate 
adenocarcinoma: 
To assess the risk of prostate cancer development, 3 populations comprising prostate 
cancer patients (PA), benign prostatic hyperplasia patients (PB) and healthy blood donors 
(PC) were enrolled and the respective GSTP1 genotype was determined. Tissue samples from 
the 105 PA patients (105 adenocarcinomas and 34 PIN lesions), and from 43 PB patients were 
tested for GSTP1 hypermethylation by conventional MSP. GST7t expression was assessed by 
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immunohistochemistry. No significant effect on prostate cancer risk was detectable for 
GSTP1 genotype, both comparing to the blood donors population (PC) (OR=1.13, 95% 
CI=0.62-2.06), and using the PB group as control population (OR=0.79, 95% CI=0.35-1.75). 
Moreover, no association was found between this genotype and tumor or BPH methylation 
status. In adenocarcinoma, a strong association between GSTP1 promotor hypermethylation 
and loss of GSTÏÏ expression was observed. This trend was not retained in PIN or BPH 
lesions. We concluded that promoter hypermethylation is an effective cause of GSTP1 
transcription silencing. Moreover, GSTP1 polymorphism is not associated with promoter 
hypermethylation nor with altered susceptibility to prostate cancer. It is suggested that 
epigenetic mechanisms may overcome the potential effects of GSTP1 variants in GSTrc 
activity. 
5. Detection of endothelin B receptor hypermethylation in early stage prostate 
adenocarcinoma: 
Prospectively collected tissue samples from 48 patients harboring clinically localized 
prostate cancer, and a control group of patients with BPH, were investigated. By MSP 
analysis, 83.3% of cases were methylated both in tumor and normal tissue of prostate cancer 
patients, as well as 91.3% of BPH samples. We concluded that EDNRB hypermethylation at 
CpG sites upstream the transcription start site does not distinguish normal from neoplastic 
prostate cells, thus precluding a role as prostate cancer marker. 
6. Mitochondrial mutations in early stage prostate cancer and bodily fluids: 
The D-loop region, 16S rRNA, and the NADH subunits of complex I were sequenced to 
identify mtDNA mutations in 16 matched PIN lesions and primary prostate cancers. Twenty 
mtDNA mutations were detected in the tumor tissue of three patients. Identical mutations 
were also identified in the PIN lesion from one patient. This patient with multiple point 
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mutations also harbored a high frequency of microsatellite instability (MSI-H) in nuclear 
mononucleotide repeat markers. Remarkably, these mutations were also detected in all (3/3) 
matched urine and plasma samples obtained from these patients. Although mitochondrial 
mutations are less common in prostate adenocarcinoma, they occur early in cancer 
progression and they can be detected in bodily fluids of early stage disease patients. 
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RÉSUMÉ 
Puisque le cancer de prostate est la malignité le plus commun chez les hommes dans 
les pays industrialisés, et son incidence, sa morbidité et sa mortalité avaient augmenté ces 
dernières années, cette Thèse a été visée identifiant des anomalies génétiques et pour définir 
les méthodologies qui peuvent contribuer pour la détection tôt du cancer de prostate. Dans la 
première partie de cette Thèse, le potentiel de la méthylation du promoteur GSTP1 comme 
repère spécifique de cancer de prostate a été étudié. Premièrement, nous avons présumé que la 
quantification de la méthylation de la glutathione-S-transferase (GSTP1) par la PCR 
méthylation-spécifique en temps réel (MSP) tiendrait compte d'une distinction entre le tissu 
néoplastique et non-néoplastique de prostate. D'ailleurs, la praticabilité de détecter ce 
changement épigénétique dans l'urine vidée, a été évaluée dans une étude préliminaire. Puis 
l'analyse quantitative conventionnelle et de MSP en temps réel ont été exécutées pour 
déterminer l'utilité clinique de la quantification de l'hypermethylation GSTP1 comme repère 
spécifique de cancer de prostate en fluides corporels (urine et plasma vidés). En conclusion, la 
relation entre le polymorphisme GSTP1 et les changements épigénétiques joints à l'expression 
de GST* dans le cancer de prostate a été étudiée. Deuxièmement, l'analyse de la méthylation 
du promoteur dans le gène de récepteur de l'endothelin B (ENDRB) a été exécutée afin 
d'essayer d'augmenter le nombre de tumeurs primaires favorables pour le criblage. L'objectif 
de la troisième partie de la Thèse était de déterminer la fréquence des mutations 
mitochondrielles dans l'adénocarcinome prostatic (et les lésions appareillées de neoplasie 
prostatic intraepitheliene - PIN), dans des échantillons de tissu et en fluides corporels, et si 
ces changements pourrait être utilisés comme repères moléculaires de tumeur. 
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1. La quantitation de l'hypermethylation de GSTP1 distingue le tissu prostatic non-
néo-plastique et l'adénocarcinome de prostate confiné au organe: 
Tissu échantillon de 69 patient avec adénocarcinome prostatic confiné au organe, 28 
lésions de PIN, et 31 patient avec hyperplasie bénin de la prostate (BPH) on été tester pour 
l'hypermethylation de le GSTP1 par quantitatif fluorogenic MSP en temps réel. Loin vérifier 
la applicabilité clinique de ce analyse nous avons exécuté une recherche aveugler éventuel 
rassembler 21 patients avec biopsies en sextante de la prostate avec niveau serique soulevé de 
prostate-spécifique antigène (PSA) (11 avec adénocarcinome identifié histologiquement, et 10 
sans évidence morphologique d'adénocarcinome). Les taux médians {GSTP1IMYOD1 
méthylé) trouvées dans le tissu prostatic hyperplastic réséqué, le neoplasie intraepithelial, et 
l'adénocarcinome étaient 0.0, 1.4, et 250.8, respectivement (P < 0,00001). Les taux médians 
de la méthylation de le GSTP1 trouvées dans les adénocarcinomes et le tissu normal de 
prostate dans des biopsies de sextant des 21 patients éventuels présentant les niveaux élevés 
de PSA également a différé de manière significative (410.6 et 0.0, respectivement; P= 
0.0007). Nous avons conclu que la quantitation du hypermethylation GSTP1 peut augmenter 
la pathologie standard en distinguant exactement entre le tissu hyperplastique et normal et le 
carcinome prostatic dans un petit échantillon de tissu. 
2. Détection de cancer de prostate dans l'urine par l'hypermethylation de le GSTP1 : 
Des spécimens appariés de la tumeur primaire, des lymphocytes périphériques du sang 
(comme controle normale) et d'une urine vidée simple ont été rassemblés de 28 patients avec 
le cancer de prostate d'une étape clinique favorable au traitement. Le ADN genomique a été 
isolée dans les échantillons et le mode de méthylation de GSTP1 examiné d'une façon sans 
visibilité utilisant MSP. Decodification des résultats a indiqué que 22 de 28 tumeurs de 
prostate (de 79%) étaient positifs pour la méthylation GSTP1. Remarquablement, dans 6 de 
22 (27%) enfermes l'ADN correspondante de sédiment d'urine était positif pour la 
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méthylation GSTP1 indiquant la présence de l'ADN néoplastique dans l'urine. En outre, il n'y 
avait aucun cas où une ADN de sédiment d'urine a hébergé la méthylation quand la tumeur 
correspondante était négative. Bien que nous ayons seulement détecté la méthylation GSTP1 
dedans sous un tiers des échantillons vidés d'urine, nous avons démontré pour la première fois 
que le diagnostic moléculaire du neoplasia de prostate dans l'urine est faisable. 
3. Hypermethylation quantitatif de le GSTP1 en fluides corporels des patients avec le 
cancer de prostate: 
Des échantillons de tissu provenant de 69 patients avec l'adénocarcinome prostatic de 
première partie et de 31 patients avec BPH ont été rassemblés. Des spécimens appariés 
d'urine et de plasma ont été obtenus preoperatively. Après traitement de sodium-bisulfite, 
l'ADN extraite a été analysée le hypermethylation du promoteur GSTP1 par MSP quantitatif 
conventionnel et en temps réel. Dans des échantillons de tissu, l'hypermethylation de le 
GSTP1 a été détecté dans 63/69 (91.3%) des patients de cancer, et 9/31 de patients de BPH 
(29%). Le MSP conventionnel a détecté le hyermethylation de le GSTP1 dans un plus grand 
nombre d'urine et de plasma que le MSP quantitatif en temps réel (53.6% contre 31.9%, 
globalment). En tous les fluides corporels positifs, le tumeur appareillée a été également 
confirmée pour être méthylée. Le hypermethylation GSTP1 a été détecté par les deux 
méthodes de MSP dans seulement 1 (3.2%) échantillons d'urine provenant d'un patient de 
BPH. Bien que non quantitatif, le MSP conventionnel est actuellement plus sensible que le 
MSP quantitatif en temps réel dans la détection de l'hypermethylation de le GSTP1 en fluides 
corporels des patients de cancer de prostate présentant la maladie cliniquement localisée. La 
valeur des déterminations quantitatives dans la surveillance et la évaluation des risques reste à 
l'explorer plus loin. 
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4. Polymorphisme de I105V et hypermethylation du promoteur du gène GSTP1 dans 
l'adénocarcinome de prostate: 
Pour évaluer le risque de développement de cancer de prostate, 3 populations comportant 
les patients avec cancer de prostate (PA), les patients avec hyperplasie prostatic bénin (PB) et 
les donateurs de sang en bonne santé (PC) ont été inscrites et le génotype GSTP1 respectif ont 
été déterminées. Des échantillons de tissu des 105 patients de PA (105 adenocarcinomes et 34 
de PIN), et provenant de 43 patients de PB ont été testés pour le hypermethylation de le 
GSTP1 par MSP. L'expression de GST» a été évaluée par immunohistochemie. Aucun effet 
significatif sur le risque de cancer de prostate n'était discernable pour le génotype GSTP1, 
tous deux comparant à la population de donateurs de sang (PC) (OR=1.13, 95% 0=0.62-
2.06), et utilisant le groupe de PB comme population de commande (OR=0.79, 95% 0=0.35-
1.75). D'ailleurs, aucune association n'a été trouvée entre cette génotype et tumeur ou 
méthylation de BPH. On a observé une association forte entre le hypermethylation du 
promoteur de le GSTP1 dans l'adénocarcinome et la perte d'expression de GST». Cette 
tendance n'a pas été maintenue dans des lésions de PIN ou de BPH. Nous avons conclu que le 
hypermethylation d'instigateur est une cause pertinente de l'amortissement de la transcription 
GSTP1. D'ailleurs, le polymorphisme GSTP1 n'est pas associé au hypermethylation du 
promoteur ni à la susceptibilité modifiée au cancer de prostate. On le suggère que les 
mécanismes épigénétiques puissent surmonter les effets potentiels des variantes GSTP1 dans 
l'activité de GSTv 
5. Détection de hypermethylation du récepteur B d'endothelin dans l'adénocarcinome 
de prostate cliniquement localisée: 
Des échantillons de tissu provenant de 48 patients hébergeant le cancer cliniquement 
localisé de prostate, et un groupe de commande de patients avec BPH, ont été étudiés. Par 
analyse de MSP, 83.3% des cas ont été méthylés dans la tumeur et le tissu normal des patients 
122 
Carmen Jerónimo - Doctoral Thesis 
de cancer de prostate aussi bien que 91.3% d'échantillons de BPH. Nous avons conclu que le 
hypermethylation de YEDNRB chez CpG situe en amont le site de début de transcription ne 
distingue pas la normale des cellules néoplastiques de prostate, de ce fait excluant un rôle en 
tant que repère de cancer de prostate. 
6. Mutations mitochondrielles en cancer de prostate cliniquement localize et fluides 
corporels: 
La région de D-boucle, le rRNA 16S, et les sous-unités du complexe de NADH ont été 
ordonnancé pour identifier des mutations de mtDNA dans 16 lésions appariées de PIN et 
cancers primaires de prostate. Vingt mutations de mtDNA ont été détectées dans le tissu de 
tumeur de trois patients. Des mutations identiques ont été également identifiées dans la lésion 
de PIN d'un patient. Ce patient présentant des mutations multiples de point a également 
hébergé une haute fréquence de l'instabilité de microsatellite (MSI-H) dans les repères 
nucléaires de répétition de mononucleotide. Remarquablement, ces mutations ont été 
également détectées dans tous les échantillons (de 3/3) urine appariée et de plasma obtenus à 
partir de ces patients. Bien que les mutations mitochondriques soient moins communes dans 
l'adénocarcinome de prostate, elles se produisent tôt dans la progression de cancer et elles 
peuvent être détectées en fluides corporels des patients de la maladie de cliniquement 
localisée. 
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RESUMO 
Considerando que o carcinoma esporádico da próstata é o tumor maligno mais comum 
em indivíduos do sexo masculino nos países industrializados e que a sua incidência, 
morbilidade e mortalidade têm vindo a aumentar, esta dissertação teve como objectivo 
identificar alterações genéticas e definir metodologias que pudessem contribuir para uma 
detecção precoce desta doença. 
No primeiro capítulo desta tese, foi investigada a utilidade do estudo da metilação do 
promotor do GSTP1 como marcador específico do adenocarcinoma da próstata. Inicialmente, 
hipotetizamos que a quantificação da metilação do GSTP1 através de um método de PCR 
específico para metilação (MSP) em tempo real permitiria a distinção entre tecido prostático 
neoplásico e não neoplásico. Adicionalmente, a exequibilidade da detecção desta alteração 
epigenética em urina de micção foi verificada num estudo preliminar. Posteriormente, foi 
realizada uma análise comparativa da eficácia de detecção da metilação do GSTP1 em fluídos 
orgânicos (urina e plasma) por MSP convencional e MSP em tempo real. Finalmente, a 
relação entre o polimorfismo do GSTP1 e as alterações epigenéticas, associadas com a 
expressão da GSTTI no carcinoma da próstata, foram objecto de estudo. 
No segundo capítulo, foi realizada a análise da metilação da região promotora do gene do 
receptor da endotelina B (ENDRB), numa tentativa de aumentar o número tumores prostáticos 
passíveis de serem rastreados. 
O terceiro capítulo da Tese teve como objectivo investigar a frequência de mutações 
mitocondriais em adenocarcinoma da próstata e lesões de neoplasia intraepitelial prostática 
(PIN), quer em tecido quer em fluídos corporais, numa tentativa de as utlilizar como 
potenciais marcadores moleculares de carcinoma da próstata. 
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1. A quantificação da hipermetilação do GSTP1 permite distinguir entre tecido 
prostático não neoplásico e adenocarcinoma confinado ao órgão: 
Amostras de tecido de 69 pacientes com adenocarcinoma da próstata em estádio precoce, 
28 lesões de PIN e 31 doentes com hiperplasia benigna da próstata (BPH) foram testadas para 
a hipermetilação do GSTP1 MSP fluorigénico quantitativo em tempo real. Adicionalmente, 
para verificar a aplicabilidade clínica deste método, foi realizado um ensaio cego em biópsias 
prostáticas de sextante recolhidas de 21 doentes com aumento do PSA sérico (11 deles com 
adenocarcinoma e 10 sem adenocarcinoma no exame histológico). Os quocientes medianos 
(GSTPJ metilada/MF<9D7) determinados em tecido prostático hiperplásico, PIN e 
adenocarcinoma foram 0,0, 1,4, e 250,8, respectivamente (P < 0,00001). O quociente 
mediano de metilação do GSTP1 em adenocarcinomas e tecido prostático normal obtido em 
biópsias de sextante dos 21 doentes com PSA sérico aumentado também diferiram 
significativamente (410,6 e 0,0, respectivamente; P = 0,0007). Concluímos que a 
quantificação da hipermetilação do GSTP1 pode aumentar a eficácia da histologia 
convencional ao discriminar com precisão tecido prostático normal de adenocarcinoma numa 
pequena amostra de tecido. 
2. Detecção de carcinoma da próstata na urina através da hipermetilação da GSTP1: 
Amostras emparelhadas de tumor primário, linfócitos do sangue periférico (controlo 
normal) e urina de micção foram obtidas de 28 pacientes com carcinoma da próstata em 
estádio clínico passível de tratamento curativo. DNA genómico foi isolado das amostras e o 
estado de metilação do GSTP1 foi examinado de forma cega, usando MSP. A descodificação 
dos resultados revelou que 22 dos 28 (79%) tumores prostáticos eram positivos para a 
metilação do GSTP1. Notavelmente, em 6 dos 22 (27%) casos, a amostra de urina 
correspondente era também positiva para a metilação do GSTP1, indicando a presença de 
DNA neoplásico na urina. Adicionalmente, em nenhum caso se verificou que um sedimento 
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urinário com metilação do GSTP1 correspondesse a um tumor negativo. Apesar de apenas 
termos detectado metilação do GSTP1 em menos de um terço dos casos, demonstrámos pela 
primeira vez que o diagnóstico molecular de carcinoma da próstata em urina é exequível. 
3. Hipermetilação quantitativa do GSTP1 em fluídos corporais de pacientes com 
carcinoma da próstata: 
Foram recolhidas amostras emparelhadas de tecido, urina e plasma (ambas pré-
operatoriamente) em 69 pacientes com carcinoma da próstata em estádio precoce e 31 
pacientes com BPH. Após tratamento do DNA extraído com bisulfito de sódio, realizou-se a 
análise da hipermetilação do promotor da GSTP1 por MSP convencional e quantitativo em 
tempo real. Nas amostras de tecido, a hipermetilação do GSTP1 foi detectada em 63/69 
(91,3%) casos de doentes com carcinoma e em 9/31 (29%) dos doentes com BPH. A MSP 
conventional detectou hipermetilação do GSTP1 em maior número de amostras de urina e 
plasma que o MSP quantitativo em tempo real (53,6% vs. 31,9%, globalmente). Em todos os 
fluídos corporais, o respective tumor estava igualmente metilado. A hipermetilação do GSTP1 
foi detectada, por ambos os métodos, em apenas uma (3,2%) amostra de urina dos doentes 
com BPH. Embora não permita quantificação, a MSP convencional é, presentemente, mais 
sensível que a MSP em tempo real na detecção de hipermetilação do GSTP1 em fluídos 
corporais de pacientes com carcinoma da próstata clinicamente localizado. O valor das 
determinações quantitativas na monitorização do carcinoma da próstata permanece por 
explorar completamente. 
4. I105V polymorphism and promoter hypermethylation of the GSTP1 gene in prostate 
adenocarcinoma: 
Por forma a determinar o risco de desenvolvimento de carcinoma da próstata, analisámos 
3 populações de indivíduos, constituídas por pacientes com carcinoma da próstata (PA), 
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pacientes com BPH (PB) e dadores de sangue saudáveis (PC), nas quais determinamos o 
respectivo genótipo para o GSTPI. Amostras de tecido de 105 doentes do grupo PA (105 
adenocarcinomas e 34 lesões de PIN), e de 43 doentes do grupo PB foram analisadas para a 
hipermetilação do GSTPI por MSP convencional. A expressão de GSTrc foi avaliada por 
imunocitoquímica. Não foi detectado um efeito significativo do genótipo do GSTPI no risco 
de desenvolvimento do carcinoma da próstata, quer comparando com os dadores de sangue 
(OR=1.13, 95% CI=0.62-2.06), quer com os doentes com BPH (OR=0.79, 95% CI=0.35-
1.75). Adicionalmente, não foi encontrada associação entre este genótipo e o estado de 
metilação no tumor ou BPH. Nos adenocarcinomas, foi observada uma forte associação entre 
a hipermetilação do promotor do GSTPI e a perda de expressão da GSTrc. Esta tendência não 
foi mantida nas lesões de PIN nem de BPH. Concluímos que a hipermetilação do promotor é 
um mecanismo eficaz de silenciamento da transcrição do GSTPI. Contrariamente, o 
polimorfismo do GSTPI não se associa à hipermetilação do promotor nem a uma 
susceptibilidade alterada ao carcinoma da próstata. Sugerimos que os mecanismos 
epigenéticos se sobrepõem aos potenciais efeitos das variantes do GSTPI na definição da 
actividade da GST71. 
5. Detecção da hipermetilação do receptor da endotelina B em adenocarcinomas da 
próstata em estádio precoce: 
Investigámos amostras de tecido, colhidas de forma prospectiva, em 48 doentes com 
adenocarcinoma da próstata clinicamente localizado, e de um grupo de controlo de pacientes 
com BPH. Através de análise por MSP, 83,3% dos casos evidenciaram metilação quer no 
tumor quer no tecido prostático normal, bem como em 91,3% dos casos de BPH. Concluímos 
que a detecção da hipermetilação do EDNRB em ilhas CpG sites a montante do local de início 
da transcrição não permite distinguir células normais de células neoplásicas da próstata, 
impedindo a sua utilização como marcador tumoral em carcinoma da próstata. 
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6. Mutações mitocondriais em carcinoma da próstata em estádio precoce e em fluídos 
orgânicos: 
Foram sequenciadas as regiões D-loop, 16S rRNA, e as subunidades do complexo I do 
NADH para identificar mutações do mtDNA em 16 lesões de PIN e respectivos 
adenocarcinomas primários da próstatas. Vinte mutações do mtDNA foram detectadas no 
tecido tumoral de 3 doentes. Mutações idênticas foram, igualmente, identificadas nas lesões 
de PIN de um dos doentes. Este paciente, que apresentava múltiplas mutações pontuais, 
também exibia uma elevada frequência de instabilidade de microsatélites (MSI-H) em 
marcadores de repetições de mononucleótidos nucleares. Notavelmente, estas mutações foram 
igualmente detectadas em todas as amostras de urina e plasma correspondentes (3/3) obtidas 
dos mesmos pacientes. Embora as mutações mitocondriais sejam menos comuns em 
carcinoma da próstata, ocorrem precocemente na progressão tumoral e são detectáveis nos 
fluídos orgânicos de doentes em estádio inicial. 
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